Huntington disease and the related disorder, dentatorubral- pallidoluysian atrophy (DRPLA)

Medicine

Volumn 76, Issue 5, 1997, Pages 305-338

  Ross, Christopher A ^a   Margolis, Russell L ^a   Rosenblatt, Adam ^a   Ranen, Neal G ^a   Becher, Mark W ^a   Aylward, Elizabeth ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; BOTULINUM TOXIN; CARBAMAZEPINE; CLOMIPRAMINE; CLONAZEPAM; DNA; DOPAMINE; FLUPHENAZINE; GLUTAMINE; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANINE NUCLEOTIDE EXCHANGE FACTOR; HALOPERIDOL; LITHIUM; MESSENGER RNA; MONOAMINE OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RESERPINE; SEROTONIN UPTAKE INHIBITOR; SPECTRIN; TETRABENAZINE; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; UBIQUITIN; VALPROATE SEMISODIUM; VALPROIC ACID;

CHOREA; CLINICAL FEATURE; COGNITIVE DEFECT; DELUSION; DENTATORUBROPALLIDOLUYSIAN ATROPHY; DEPRESSION; DISEASE COURSE; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYMPTOM; GENE; GENETIC LINKAGE; HALLUCINATION; HUMAN; HUNTINGTON CHOREA; INSOMNIA; MOTOR DYSFUNCTION; NONHUMAN; ORTHOSTATIC HYPOTENSION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW;

CHOREA; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; NEURODEGENERATIVE DISEASES;

EID: 0030868770     PISSN: 00257974     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005792-199709000-00001     Document Type: Review

References (452)

1. Adler AJ, Danielsen M, Robins DM. Androgen-specific gene activation via a consensus glucocorticoid response element is determined by interaction with nonreceptor factors. Proc Natl Acad Sci U S A 89: 11660-11663, 1992.
2. Alam MR, Caldwell BD, Johnson PC, Darlington DN, Mains RE, Eipper BA. Novel proteins that interact with the COOH-terminal cytosolic routing determinants of an integral membrane peptide-processing enzyme. J Biol Chem 271: 28636-28640, 1996.
3. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 12: 366-375, 1989.
4. Albin RL, Young AB, Penney JB, Handelin B, Balfour R, Anderson KD, Markel DS, Tourtellotte WW, Reiner A. Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease. N Engl J Med 322: 1293-1298, 1990.
5. Albin RL, Greenamyre JT. Alternative excitotoxic hypotheses. Neurology 42: 733-738, 1992.
6. Albin RL, Reiner A, Anderson KD, Dure LS IV, Handelin B, Balfour R, Whetsell WO, Penney JB, Young AB. Preferential loss of striato external pallidal projection neurons in presymptomatic Huntington's disease. Ann Neurol 31: 425-430, 1992.
7. Albin RL. Selective neurodegeneration in Huntington's disease [editorial]. Ann Neurol 38: 835-836, 1995.
8. Albin RL, Tagle DA. Genetics and molecular biology of Huntington's disease. Trends Neurosci 18: 11-14, 1995.
9. Allitto BA, MacDonald ME, Bucan M, Richards J, Romano D, Whaley WL, Falcone B, Ianazzi J, Wexler NS, Wasmuth JJ, Collins FS, Lehrach H, Haines JL, Gusella JF. Increased recombination adjacent to the Huntington disease-linked D4S10 marker. Genomics 9: 104-112, 1991.
10. Almqvist E, Spence N, Nichol K, Andrew SE, Vesa J, Peltonen L, Anvret M, Goto J, Kanazawa I, Goldberg YP, Hayden MR. Ancestral differences in the distribution of the 2642 glutamic acid polymorphism is associated with varying CAG repeat lengths on normal chromosomes: Insights into the genetic evolution of Huntington disease. Hum Mol Genet 4: 207-214, 1995.
11. Ambrose CM, Duyao MP, Barnes G, Bates GP, Lin CS, Srinidhi J, Baxendale S, Hummerich H, Lehrach H, Altherr M, Wasmuth J, Buckler A, Church D, Housman D, Berks M, Micklem G, Durbin R, Dodge A, Read A, Gusella J, MacDonald ME. Structure and expression of the Huntington's disease gene: Evidence against simple inactivation due to an expanded CAG repeat. Somat Cell Molec Genet 20: 27-38, 1994.
12. Amos W, Sawcer SJ, Freakes RW, Rubinsztein DC. Microsatellites show mutational bias and heterozygote instability. Nat Genet 13: 390-391, 1996.
13. Andrade MA, Bork P. HEAT repeats in the Huntington's disease protein. Nat Genet 11: 115-116, 1995.
14. Andrew SE, Goldberg YP, Kremer B, Telenius H, Theilmann J, Adam S, Starr E, Squitieri F, Lin B, Kalchman MA, Graham RK, Hayden MR. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat Genet 4: 398-403, 1993.
15. Andrew SE, Goldberg YP, Kremer B, Squitieri F, Theilmann J, Zeisler J, Telenius H, Adam S, Almquist E, Anvret M, Lucotte G, Stoessl AJ, Campanella G, Hayden MR. Huntington disease without CAG expansion: Phenocopies or errors in assignment? Am J Hum Genet 54: 852-863, 1994.
16. Andrew SE, Goldberg YP, Theilmann J, Zeisler J, Hayden MR. A CCG repeat polymorphism adjacent to the CAG repeat in the Huntington disease gene: Implications for diagnostic accuracy and predictive testing. Hum Mol Genet 3: 65-67, 1994.
17. Aronin N, Chase K, Young C, Sapp E, Schwarz C, Matta N, Kornreich R, Landwehrmeyer B, Bird E, Beal MF, Vonsattel J-P, Smith T, Carraway R, Boyce FM, Young AB, Penney JB, DiFiglia M. CAG expansion affects the expression of mutant huntingtin in the Huntington's disease brain. Neuron 15: 1193-1201, 1995.
18. Ashizawa T, Wong L-JC, Richards CS, Caskey CT, Jankovic J. CAG repeat size and clinical presentation in Huntington's disease. Neurology 44: 1137-1143, 1994.
19. Aylward EH, Anderson NB, Bylsma FW, Wagster MV, Barta PE, Sherr M, Feeney J, Davis A, Ranen N, Pearlson GD, Ross CA. Frontal lobe volume in patients with Huntington's disease. Neurology (in press).
20. Aylward EH, Brandt J, Codori AM, Mangus RS, Barta PE, Harris GJ. Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons. Neurology 44: 823-828, 1994.
21. Aylward EH, Codori A-M, Barta PE, Pearlson GD, Harris GJ, Brandt J. Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. Arch Neurol 53: 1293-1296, 1996.
22. Aylward EH, Li Q, Stine OC, Ranen N, Sherr M, Barta PE, Bylsma FW, Pearlson GD, Ross CA. Longitudinal change in basal ganglia volume in patients with Huntington's disease. Neurology 48: 394-399, 1997.
23. Bachman DS, Butler IJ, McKhann GM. The long-term treatment of juvenile Huntington's chorea with dipropylacetic acid. Neurology 27: 193-197, 1977.
24. Banfi S, Servadio A, Chung M-Y, Kwiatkowski TJ Jr, McCall AE, Duvick LA, Shen Y, Roth EJ, Orr HT, Zoghbi HY. Identification and characterization of the gene causing type 1 spinocerebellar ataxia. Nat Genet 7: 513-520, 1994.
25. Barnes GT, Duyao MP, Ambrose CM, McNeil S, Perischetti F, Srinidhi J, Gusella JF, MacDonald ME. Mouse Huntington's disease gene homolog (Hdh). Somat Cell Mol Genet 20: 87-97, 1994.
26. Bao J, Sharp AH, Wagster MV, Becher M, Schilling G, Ross CA, Dawson VL, Dawson TM. Expansion of poly-glutamine repeat in huntingtin leads to abnormal protein interactions involving calmodulin. Proc Natl Acad Sci U S A 93: 5037-5042, 1996.
27. Barr AN, Fischer JH, Koller WC, Spunt AL, Singhal A. Serum haloperidol concentration and choreiform movements in Huntington's disease. Neurology 38: 84-88, 1988.
28. Bates GP, MacDonald ME, Baxendale S, Youngman S, Lin C, Whaley WL, Wasmuth JJ, Gusella JF, Lehrach H. Denned physical limits of the Huntington disease gene candidate region. Am J Hum Genet 49: 7-16, 1991.
29. Bates GP, Valdes J, Hummerich H, Baxendale S, Le Paslier DL, Monaco AP, Tagle D, MacDonald ME, Altherr M, Ross M, Brownstein BH, Bentley D, Wasmuth JJ, Gusella JF, Cohen D, Collins F, Lehrach H. Characterization of a yeast artificial chromosome contig spanning the Huntington's disease gene candidate region. Nat Genet 1: 180-187, 1992.
30. Baxendale S, MacDonald ME, Mott R, Francis F, Lin C, Kirby SF, James M, Zehetner G, Hummerich H, Valdes J, Collins FS, Deaven LJ, Gusella JF, Lehrach H, Bates GP. A cosmid contig and high resolution restriction map of the 2 megabase region containing the Huntington's disease gene. Nat Genet 4: 181-186, 1993.
31. Baxendale S, Abdulla S, Elgar G, Buck D, Berks M, Micklem G, Durbin R, Bates G, Brenner S, Beck S, Lehrach H. Comparative sequence analysis of the human and pufferfish Huntington's disease genes. Nat Genet 10: 67-76, 1995.
32. Beal MF, Hyman BT, Koroshetz W. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trends Neurosci 16: 125-128, 1986.
33. Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, Martin JB. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 321: 168-171, 1986.
34. Beal MF. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol 31: 119-130, 1992.
35. Beal MF, Brouillet E, Jenkins BG, Ferrante RJ, Kowall NW, Miller JM, Storey E, Srivastava R, Rosen BR, Hyman BT. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3 nitropropionic acid. J Neurosci 13: 4181-4192, 1993.
36. 10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate. Ann Neurol 36: 882-888, 1994.
37. Beal MF, Ferrante RJ, Henshaw R, Matthews RT, Chan PH, Kowall NW, Epstein CJ, Schulz JB. 3-Nitropropionic acid neurotoxicity is attenuated in copper/zinc superoxide dismatase transgenic mice. J Neurochem 65: 919-922, 1995.
38. Becher MW, Rubinsztein DC, Leggo J, Wagster MV, Stine OC, Ranen NG, Franz ML, Abbott MH, Sherr M, MacMillian JC, Barron L, Porteous M, Harper PS, Ross CA. Dentato-rubral and pallido-luysian atrophy (DRPLA): Clinical and neuropathological findings in genetically confirmed North American and European pedigrees. Mov Disord (in press).
39. Benjamin CM, Adam S, Wiggins S, Theilmann JL, Copley TT, Bloch M, Squitieri F, McKellin W, Cox S, Brown SA, Kremer HPH, Burgess M, Meshino W, Summers A, MacGregor D, Buchanan J, Greenberg C, Carson N, Ives E, Frecker M, Welch JP, Fuller A, Rosenblatt D, Miller S, Dufrasne S, Roy M. Andermann E, Prevost C, Khalifa M, Girard K, Taylor S, Hunter A, Goldsmith C, Whelan D, Eisenberg D, Soltan H, Kane J, Shokeir MHK, Gibson A, Cardwell, S, Bamforth S, Grover S, Suchowersky O, Klimek M, Garber T, Gardner HA, MacLeod P, Hayden MR. Proceed with care: Direct predictive testing for Huntington disease. Am J Hum Genet 55: 606-617, 1994.
40. Bhide PG, Day M, Sapp E, Schwarz C, Sheth A, Kim J, Young AB, Penney J, Golden J, Aronin N, DiFiglia. Expression of normal and mutant huntingtin in the developing brain. J Neurosci 16: 5523-5535, 1996.
41. Bird ED, Caro AJ, Pilling JB. A sex related factor in the inheritance of Huntington's chorea. Ann Hum Genet 37: 255-260, 1974.
42. Bird TD, Carlson CB, Hall JG. Familial essential ('benign') chorea. J Med Genet 13: 357-362, 1976.
43. Bird TD, Bennett RL. Why do DNA testing? Practical and ethical implications of new neurogenetic tests. Ann Neurol 38: 141-146, 1995.
44. Boehnke M, Conneally PM, Lange K. Two models for a maternal factor in the inheritance of Huntington's disease. Am J Hum Genet 35: 845-860, 1983.
45. Bork P, Sudol M. The WW domain: A signalling site in dystrophin? Trends Biochem Sci 19: 531-533, 1994.
46. Brackenridge CJ. The relation of type of initial symptoms and line of transmission to ages at onset and death in Huntington's disease. Clin Genet 2: 287-297, 1971.
47. Brando LJ, Yolken R, Herman MM, Kleinman JE, Ross CA, Torrey EF. Analysis of the DRPLA triplet repeat in brain tissue and leukocytes from schizophrenics. Psychiatric Genet 6: 1-5, 1996.
48. Brandt J, Strauss ME, Larus J, Jensen B, Folstein SE, Folstein MF. Clinical correlates of dementia and disability in Huntington's disease. J Clin Neuropsychol 6: 401-412, 1984.
49. Brandt J, Butters N. The neuropsychology of Huntington's disease. Trends Neurosci 9: 118-120, 1986.
50. Brandt J, Folstein SE, Folstein MF. Differential cognitive impairment in Alzheimer's disease and Huntington's disease. Ann Neurol 23: 555-561, 1988.
51. Brandt J, Quaid KA, Folstein SE, Garber P, Maestri NE, Abbott MH, Slavney PR, Franz ML, Kasch L, Kazazian HH Jr. Presymptomatic diagnosis of delayed-onset disease with linked DNA markers: The experience in Huntington's disease. JAMA 261: 3108-3114, 1989.
52. Brandt J. The Hopkins Verbal Learning Test: Development of a new memory test with six equivalent forms. Clin Neuropsychologist 5: 125-142, 1991.
53. Brandt J, Corwin J, Krafft L. Is verbal recognition memory really different in Alzheimer's and Huntington's disease? J Clin Exper Neuropsychol 14: 773-784, 1992.
54. Brandt J. Cognitive investigations in Huntington's disease. In: LS Cermak, ed. Neuropsychological explorations of memory and cognition: Essays in honor of Nelson Butters. New York: Plenum, pp 135-146 1994.
55. Brandt J, Bylsma FW, Gross R, Stine OC, Ranen N, Ross CA. Trinucleotide repeat length and clinical progression in Huntington's disease. Neurology 46: 527-531, 1996.
56. Bredesen DE. Neural apoptosis. Ann Neurol 38: 839-851, 1995.
57. Bredt DS, Snyder SH. Nitric oxide a novel neuronal messenger. Neuron 8: 3-11, 1992.
58. Britton JW, Uitti RJ, Ahlskog JE, Robinson RG, Kremer B, Hayden MR. Hereditary late-onset chorea without significant dementia: Genetic evidence for substantial phenotypic variation in Huntington's disease. Neurology 45: 443-447, 1995.
59. Brouillet E, Jenkins BG, Hyman BT, Ferrante RJ, Kowall NW, Srivastava R, Samanta-Roy D, Rosen BR, Beal MF. Age-dependent vulnerability of the striatum to the mitochondrial toxin 3 nitropropionic acid. J Neurochem 60: 356-359, 1993.
60. Brouillet E, Hantraye P, Ferrante RJ, Dolan R, Leroy-Willig A, Kowall NW, Beal MF. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc Natl Acad Sci U S A 92: 7105-7109, 1995.
61. Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muqit MMK, Bird ED, Beal MF. Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia Ann Neurol 41: 646-653, 1997.
62. Bruyn GW. Huntington's chorea: Historical, clinical and laboratory synopsis. In: Vinken PJ, Bruyn GW, eds. Diseases of the basal ganglia. Amsterdam: North-Holland, p 298-378, 1968.
63. Buetow KH, Shiang R, Yang P, Nakamura Y, Lathrop GM, White R, Wasmuth JJ, Wood S, Berdahl LD, Leysens NJ, Ritty TM, Wise ME, Murray JC. A detailed multipoint map of human chromosome 4 provides evidence for linkage heterogeneity and position-specific recombination rates. Am J Hum Genet 48: 911-925, 1991.
64. Bull PC, Thomas GR, Rommens JM, Forbes JR, Cox DW. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet 5: 328-337, 1993.
65. Burke JR, Wingfield MS, Lewis KE, Roses AD, Lee JE, Hulette C, Pericak-Vance MA, Vance JM. The Haw River Syndrome: Dentatorubropallidoluysian atrophy (DRPLA) in an African-American family. Nat Genet 7: 521-524, 1994.
66. Burke JR, Enghild JJ, Martin ME, Jou YS, Myers RM, Roses AD, Vance JM, Strittmatter WJ. Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH. Nat Med 2: 347-350, 1996.
67. Burns A, Folstein SE, Brand J, Folstein MF. Clinical assessment of irritability, aggression, and apathy in Huntington and Alzheimer disease. J Nerv Ment Dis 178: 20-26, 1990.
68. Burright EN, Clark HB, Servadio A, Matilla T, Feddersen RM, Yunis WS, Duvick LA, Zoghbi HY, Orr HT. SCA1 transgenic mice: A model for neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell 82: 937-948, 1995.
69. Butters N, Wolfe J, Granholm E. An assessment of verbal recall, recognition and fluency abilities in patients with Huntington's disease. Cortex 22: 11-32, 1986.
70. Cammarata S, Caponnetto C, Tabaton M. Ubiquitin-reactive neurites in cerebral cortex of subjects with Huntington's chorea: A pathological correlate of dementia? Neurosci Lett 156: 96-98, 1993.
71. Campbell AMG, Corner BD, Norman RM, Urich H. The rigid form of Huntington's disease. J Neurol Neurosurg Psychiatry 24: 71-77, 1961.
72. Cancel G, Dürr A, Didierjean O, Imbert G, Bürk K, Lezin A, Belal S, Benomar A, Abada-Bendib M, Vial C, Guimarães J, Chneiweiss H, Stevanin G, Yvert G, Abbas N, Saudou F, Lebre A-S, Yahyaoui M, Hentati F, Vernant J-C, Klockgether T, Mandel J-L, Agid Y, Brice A. Molecular and clinical correlations in spinocerebellar ataxia 2: A study of 32 families. Hum Mol Genet 6: 709-715, 1997.
73. Caskey CT, Pizzuti A, Fu YH, Fenwick RG Jr, Nelson DL. Triplet repeat mutations in human disease. Source Science 256: 784-789, 1992.
74. Cha J-HJ, Dure LS IV. Trinucleotide repeats in neurologic diseases: An hypothesis concerning the pathogenesis of Huntington's disease, Kennedy's disease, and Spinocerebellar ataxia type I. Life Science 54: 1459-1464, 1994.
75. Choi DW. Excitotoxic cell death. J Neurobiol 23: 1261-1276, 1992.
76. Claes S, Van Zand K, Legius E, Dom R, Malfroid M, Baro F, Godderis J, Cassiman J-J. Correlations between triplet repeat expansion and clinical features in Huntington's disease. Arch Neurol 113: 749-753, 1995.
77. Collins FS. Positional cloning moves from perditional to traditional. Nat Genet 9: 347-350, 1995.
78. Connarty M, Dennis NR, Patch JN, MacPherson JN, Harvey JF. Molecular re-investigation of patients with Huntington's disease in Wessex reveals a family with dentatorubral and pallidoluysian atrophy. Hum Genet 97: 76-78, 1996.
79. Conneally PM, Haines JL, Tanzi RE, Wexler NS, Penchaszadeh GK, Harper PS, Folstein SE, Cassiman JJ, Myers RH, Young AM, Hayden MR, Falek A, Tolosa ES, Crespi S, DiMaio L, Holmgren G, Anvret M, Kanazawa I, Gusella JF. Huntington disease: No evidence for locus heterogeneity. Genomics 5: 304-308, 1989.
80. Cotman CW, Monaghan DT, Ottersen OP, Storm-Mathisen J. Anatomical organization of excitatory amino acid receptors and their pathways. Trends Neurosci 10: 273-280, 1987.
81. Coyle JT, Schwarcz R. Lesion of striatal neurons with kainic acid provides a model for Huntington's chorea. Nature 263: 244-246, 1976.
82. Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 262: 689-695, 1993.
83. Critchley M. The history of Huntington's chorea [editorial]. Psychol Med 14: 725-727, 1984.
84. Cudkowicz M, Kowall NW. Degeneration of pyramidal projection neurons in Huntington's disease cortex. Ann Neurol 27: 200-204, 1990.
85. Currier RD, Jackson JF, Meydrech EF. Progression rate and age at onset are related in autosomal dominant neurologic diseases. Neurology 32: 907-909, 1982.
86. Cummings JL, Gosenfeld LE, Houlihan JP, McCaffrey T. Neuropsychiatric disturbances associated with idiopathic calcification of the basal ganglia. Biol Psychiatry 18: 591-601, 1983.
87. Danek A, Uttner I, Vogl T, Tatsch K, Witt TN. Cerebral involvement in McLeod syndrome. Neurology 44: 117-129, 1994.
88. Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, Scherzinger E, Wanker EE, Mangiarini L, Bates GP. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90: 537-548, 1997.
89. Dawson TM, Dawson VL, Snyder SH. A novel neuronal messenger molecule in the brain: The free radical, nitric oxide. Ann Neurol 32: 297-311, 1992.
90. Dawson TM, Steiner JP, Dawson VL, Dinerman JL, Uhl GR, Snyder SH. Immunosuppressant FK506 enhances phosphorylation of nitric oxide syntheses and protects against glutamate neurotoxicity. Proc Natl Acad Sci U S A 90: 9808-9812, 1993.
91. Dawson VL, Kizushi VM, Huang PL, Snyder SH, Dawson TM. Resistance to neurotoxicity in cortical cultures from neuronal nitric oxide syntheses-deficient mice. J Neurosci 16: 2479-2487, 1996.
92. Debant A, Serra-Pages C, Seipel K, O'Brien S, Tang M, Park S-H, Streuli M. The multidomain protein Trio binds the LAR transmembrane tyrosine phosphatase, contains a protein kinase domain, and has separate rac-specific and rho-specific guanine nucleotide exchange factor domains. Proc Natl Acad Sci U S A 93: 5466-5471, 1996.
93. Deka R, Miki T, Yin S-J, McGarvey ST, Shriver MD, Bunker CH, Raskin S, Hundrieser J, Ferrell RE, Chakraborty R. Normal CAG repeat variation at the DRPLA locus in world populations. Am J Hum Genet 57: 508-511, 1995.
94. De la Monte SM, Vonsattel JP, Richardson EP. Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. J Neuropathol Exp Neurol 47: 516-525, 1988.
95. De Rooij KE, Dorsman JC, Smoor MA, Den Dunnen JT, Van Ommen G-JB. Subcellular localization of the Huntington's disease gene product in cell lines by immunofluorescence and biochemical subcellular fractionation. Hum Mol Genet 5: 1093-1099, 1996.
96. DeStafano AL, Cupples LA, Maciel P, Gaspar C, Radvany J, Dawson DM, Sudarsky L, Corwin L, Coutinho P, MacLeod P, Sequeiros J, Rouleau GA, Farrer LA. A familial factor independent of CAG repeat length influences age at onset of Machado-Joseph disease. Am J Hum Genet 59: 119-127, 1996.
97. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, VonSattel JP, Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites m brain. Science (in press).
98. DiFiglia M, Sapp E, Chase K, Schwarz C, Meloni A, Young C, Martin E, Vonsattel JP, Carraway R, Reeves SA, Boyce FM, Aronin N. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 14: 1075-1081, 1995.
99. Djian P, Hancock JM, Chana HS. Codon repeats in genes associated with human diseases: Fewer repeats in the genes of nonhuman primates and nucleotide substitutions concentrated at the sites of reiteration. Proc Natl Acad Sci U S A 93: 417-421, 1996.
100. Doerflinger N, Linder C, Ouahchi K, Gyapay G, Weissenbach J, Le Paslier D, Rigault P, Belal S, Hamida CB, Hentati F, Hamida MB, Pandolfo M, DiDonato S, Sokol R, Kayden H, Landrieu P, Durr A, Brice A, Goutières F, Kohlschütter, Sabouraud P, Benomar A, Yahyaoui M, Mandel J-L, Koenig M. Ataxia with vitamin E deficiency: Refinement of genetic localization and analysis of linkage disequilibrium by using new markers in 14 families. Am J Hum Genet 56: 1116-1124, 1995.
101. Dom R, Malfroid M, Baro F. Neuropathology of Huntington's chorea. Studies of the ventrobasal complex of the thalamus. Neurology 26: 64-68, 1976.
102. Duboule D, Haenlin M, Galliot B, Mohier E. DNA sequences homologous to the Drosophila opa repeat are present in murine mRNAs that are differentially expressed in fetuses and adult tissues. Mol Cell Biol 7: 2003-2006, 1987.
103. Dugan LL, Sensi SL, Canzoniero LMT, Handran SD, Rothman SM, Lin T-S, Goldberg MP. Mitochondrial production of reactive oxygen species in cortical neurons following exposure to N-methyl-D-aspartate. J Neurosci 15: 6377-6388, 1995.
104. Durbach N, Hayden MR. George Huntington: The man behind the eponym. J Med Genet 30: 406-409, 1993.
105. Dure LS IV, Landwehrmeyer GB, Golden J, McNeil SM, Ge P, Aizawa H, Huang Q, Ambrose CM, Duyao MP, Bird ED, DiFiglia M, Gusella JF, MacDonald ME, Penney JB, Young AB, Vonsattel J-P. IT15 gene expression in fetal human brain. Brain Res 659: 33-41, 1994.
106. Dürr A, Dodé C, Hahn V, Pêcheux C, Pillon B, Feingold J, Kaplan J-C, Agid Y, Brice A. Diagnosis of "sporadic" Huntington's disease. J Neurol Sci 129: 51-55, 1995.
107. Duyao M, Ambrose C, Myers R, Novelletto A, Persichetti F, Frontali M, Folstein S, Ross C, Franz M, Abbott M, Gray J, Conneally P, Young A, Penney J, Hollingsworth Z, Shoulson I, Lazzarini A, Falek A, Koroshetz W, Sax D, Bird E, Vonsattel J, Bonilla E, Alvir J, Conde B, Cha J-H, Dure L, Gomez F, Ramos M, Sanchez-Ramos J, Snodgrass S, de Young M, Wexler N, Moscowitz C, Penchaszadeh G, MacFarlane H, Anderson M, Jenkins B, Srinidhi J, Barnes G, Gusella J, MacDonald M. Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat Genet 4: 387-392, 1993.
108. Duyao MP, Auerbach AB, Ryan A, Persichetti F, Barnes GT, McNeil SM, Ge P, Vonsattel JP, Gusella JF, Joyner AL, MacDonald ME. Inactivation of the mouse Huntington's disease gene homolog HDH. Science 269: 407-410, 1995.
109. Dyken PR. Reconsideration of the classifications of the neuronal ceroid-lipofuscinoses. Am J Med Genet Suppl 5: 69-84, 1988.
110. Emerich DF, Lindner MD, Winn SR, Chen E-Y, Frydel BR, Kordower JH. Implants of encapsulated human CNTF-producing fibroblasts prevent behavioral deficits and striatal degeneration in a rodent model of Huntington's disease. J Neurosci 16: 5168-5181, 1996.
111. Emerich DF, Winn SR, Hantraye PM, Peschanski M, Chen E-Y, Chu Y, McDermott P, Baetge EE, Kordower JH. Protective effect of encapsulated cells producing neurotrophic factor of CNTF in a monkey model of Huntington's disease. Nature 386: 395-399, 1997.
112. Farmer TW, Wingfield MS, Lynch SA, Vogel FS, Hulette C, Katchinoff B, Jacobson PL. Ataxia, chorea, seizures, and dementia. Pathologic features of a newly defined familial disorder. Arch Neurol 46: 774-779, 1989.
113. Farmer TW, Wingfield MS, Jacobson PL, Katchinoff BL, Lynch SA, Curnes JT. Neuroimaging of a new familial disorder: Ataxia, chorea, seizures, and dementia. J Neuroimag 1: 123-128, 1991.
114. Farrer LA, Conneally PM. A genetic model for age at onset in Huntington disease. Am J Hum Genet 37: 350-357, 1985.
115. Farrer LA, Cupples LA, Waiter P, Conneally PM, Gusella JF, Myers RH. The normal Huntington disease (HD) allele, or a closely linked gene, influences age at onset of HD. Am J Hum Genet 53: 125-130, 1993.
116. Feigin A, Kieburtz K, Bordwell K, Como P, Steinberg K, Sotack J, Zimmerman C, Hickey C, Orme C, Shoulson I. Functional decline in Huntington's disease. Mov Disord 10: 211-214, 1995.
117. Feigin A, Kieburtz K, Como P, Hickey C, Claude K, Abwender D, Zimmerman C, Steinberg K, Shoulson I. Assessment of Coenzyme Q10 tolerability in Huntington's disease. Mov Disord 11: 321-323, 1996.
118. Fernandes-Alnemri T, Litwack G, Alnemri ES. CPP32, a novel human apoptosis protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1-beta-converting enzyme. J Biol Chem 269: 30761-30764, 1994.
119. Ferrante RJ, Kowall NW, Beal MF, Richardson EP Jr, Bird ED, Martin JB. Selective sparing of a class of striatal neurons in Huntington's disease. Science 230: 561-563, 1985.
120. Ferrante RJ, Beal MF, Kowall NW, Richardson EP, Martin JB. Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease. Brain Res 411: 162-166, 1987.
121. Ferrante RJ, Kowall NW, Beal MF, Martin JB, Bird ED, Richardson EP. Morphologic and histochemical characteristics of a spared subset of striatal neurons in Huntington's disease. J Neuropathol Exp Neurol 46: 12-27, 1987.
122. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": A practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res 2: 189-198, 1975.
123. Folstein SE, Abbott M, Moser R, Parhad I, Clark A, Folstein M. A phenocopy of Huntington's disease: Lucunar infarcts of the corpus striatum. Johns Hopkins Med J 148: 104-108, 1981.
124. Folstein SE, Jensen B, Leigh RJ, Folstein MF. The measurement of abnormal movement: Methods developed for Huntington's disease. Neurobehav Toxicol Teratol 5: 605-609, 1983.
125. Folstein SE, Franz ML, Jensen BA, Chase GA, Folstein MF. Conduct disorder and affective disorder among the offspring of patients with Huntington's disease. Psycholog Med 13: 45-52, 1983.
126. Folstein SE, Abbott MH, Franz ML, Huang S, Chase GA, Folstein MF. Phenotypic heterogeneity in Huntington disease. J Neurogenet 1: 175-184, 1984.
127. Folstein SE, Phillips JA III, Meyers DA, Chase GA, Abbott MH, Franz ML, Waber PG, Kazazian HH Jr, Conneally PM, Hobbs W, Tanzi R, Faryniarz A, Gibbons K, Gusella J. Huntington's disease: Two families with differing clinical features show linkage to the G8 probe. Science 229: 776-779, 1985.
128. Folstein SE, Leigh RJ, Parhad IM, Folstein MF. The diagnosis of Huntington's disease. Neurology 36: 1279-1283, 1986.
129. Folstein SE, Chase G, Wahl WE, McDonnell AM, Folstein MF. Huntington disease in Maryland: Clinical aspects of racial variation. Am J Hum Genet 41: 168-179, 1987.
130. Folstein SE, Conneally PM, Wexler NS, Gusella JF. Localization of the Huntington's disease gene to a small segment of chromosome 4 flanked by D4S10 and the telomere. Cell 50: 565-571, 1987.
131. Folstein SE. Huntington's disease. A disorder of families. Baltimore: Johns Hopkins University Press, 1989.
132. Ford MF. Treatment of depression in Huntington's disease with monoamine oxidase inhibitors. BrJ Psychiatry 149: 654-656, 1986.
133. Foroud T, Siemers E, Heindorfer D, Bill DJ, Hodes ME, Norton JA, Conneally PM, Christian JC. Cognitive scores in carriers of Huntington's disease gene compared to noncarriers. Ann Neurol 37: 657-664, 1995.
134. Furtado S, Suohowersky O, Rewcastle B, Graham L, Klimek ML, Garber A. Relationship between trinucleotide repeats and neuropathological changes in Huntington's disease. Ann Neurol 39: 132-136, 1996.
135. Gacy AM, Goeliner G, Juranic N, Macura S, McMurray T. Trinucleotide repeats that expand in human disease form hairpin structures in vitro. Cell 81: 533-540, 1995.
136. Gellera C, Meoni C, Castellotti B, Zappacosta B, Girotti F, Taroni F, DiDonato S. Errors in Huntington's disease diagnostic test caused by trinucleotide deletion in the IT15 gene. Am J Hum Genet 59: 475-477, 1996.
137. Gerber H-P, Seipel K, Georgiev O, Höfferer M, Hug M, Rusconi S, Schaffner W. Transcriptional activation modulated by homopolymeric glutamine and proline stretches. Science 263: 808-811, 1994.
138. Gibb WRG, Luthert PJ, Marsden CD. Corticobasal degeneration Brain 112: 1171-1192, 1989.
139. Gilliam TC, Bucan M, MacDonald ME, Zimmer M, Haines JL, Cheng SV, Pohl TM, Meyers RH, Whaley WL, Allitto BA, Faryniarz A, Wasmuth JJ, Frischauf A-M, Conneally M, Lehrach H, Gusella JF. A DNA segment encoding two genes very tightly linked to Huntington's disease. Science 238: 950-952, 1987.
140. Giordani B, Berent S, Boivin MJ, Penney JB, Lehtinen S, Markel DS, Hollingsworth Z, Butterbaugh G, Hichwa RD, Gusella JF, Young AB. Longitudinal neuropsychological and genetic linkage analysis of persons at risk for Huntington's disease. Arch Neurol 52: 59-64, 1995.
141. Goldberg YP, Andrew SE, Theilmann J, Kremer B, Squitieri F, Telenius H, Brown JD, Hayden MR. Familial predisposition to recurrent mutations causing Huntington's disease: genetic risk to sibs of sporadic cases. J Med Genet 30: 987-990, 1993.
142. Goldberg YP, Kalchman MA, Zeisler J, Graham R, Koide HB, O'Kusky J, Sharp AH, Ross CA, Jirik F, Hayden MR. Absence of disease phenotype and intergenerational stability of the CAG repeat in transgenic mice expressing the human Huntington disease transcript. Hum Mol Genet 5: 177-185, 1996.
143. Goldberg YP, Kremer B, Andrew SE, Theilmann J, Graham RK, Squitieri F, Telenius H, Adam S, Sajoo A, Starr E, Heiberg A, Wolff G, Hayden MR. Molecular analysis of new mutations for Huntington's disease: Intermediate alleles and sex of origin effects Nat Genet 5: 174-179, 1993.
144. Goldberg YP, Telenius H, Hayden MR. The molecular genetics of Huntington's disease. Curr Opin Neurol 7: 325-332, 1994.
145. Goldberg YP, McMurray CT, Zeisler J, Almqvist E, Sillence D, Richards F, Gacy AM, Buchanan JB, Telenius H, Hayden MR. Increased instability of intermediate alleles in families with sporadic Huntington disease compared to similar sized intermediate alleles in the general population. Hum Mol Genet 4: 1911-1918, 1995.
146. Goldberg YP, Nicholson DW, Rasper DM, Kalchman MA, Koide HB, Graham RK, Bromm M, Kazemi-Esfarjani P, Thornberry NA, Vaillancourt JP, Hayden MR. Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract Nat Genet 13: 442-449, 1996.
147. Gordenin DA, Kunkel TA, Resnick MA. Repeat expansion - all in a flap? Nat Genet 16: 116-118, 1997.
148. Goto I, Tobimatsu S, Ohta M, Hosokawa S, Shibasaki H, Kuroiwa Y. Dentatorubro-pallidoluysian degeneration: Clinical neuro-opthalmologic, biochemical, and pathologic studies on autosomal dominant form. Neurology 32: 4405-4409, 1982.
149. Leu(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature 348: 651-653, 1990.
150. Graveland GA, Williams RS, DiFiglia M. Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. Science 227: 770-773, 1985.
151. Graveland GA, Williams RS, DiFiglia M. A Golgi study of the human neostriatum: Neurons and afferent fibers. J Comp Neurol 234: 317-333, 1985.
152. Green H. Human genetic diseases due to codon reiteration: Relationship to an evolutionary mechanism. Cell 74: 955-956, 1993.
153. Greene JC, Greenamyre JT. Manipulation of membrane potential modulations malonate-induced striatal excitotoxicity in vivo Soc Neurosci Abstr 21: 1039, 1995.
154. Greene JG, Nizol R, Jamesion H. Reality orientation with psychogeriatic patients. Behav Res Ther 17: 615-617, 1979.
155. Gu M, Gash MT, Mann VM, Javoy-Agid F, Cooper JM, Schapira AHV. Mitochondrial defect in Huntington's disease caudate nucleus Ann Neurol 39: 385-389, 1996.
156. Gusella JF, Wexler N, Conneally P, Naylor SL, Anderson MA, Tanzi RE, Watkins PC, Ottina K, Wallace MR, Sakaguchi AY, Young AB, Shoulson I, Bonilla E, Martin JB. A polymorphic DNA marker genetically linked to Huntington's disease. Nature 306: 234-238, 1983.
157. Gusella JF. Location cloning strategy for characterizing genetic defects in Huntington's disease and Alzheimer's disease. FASEB J 3: 2036-2041, 1989.
158. Gusella JF, MacDonald ME, Ambrose CM, Duyao MP. Molecular genetics of Huntington's disease. Arch Neurol 50: 1157-1163, 1993.
159. Gusella JF, MacDonald ME. Huntington's disease. Semin Cell Biol 6: 21-28, 1995.
160. Gusella JF, MacDonald ME. Trinucleotide instability: A repeating theme in human inherited disorders. Annu Rev Med 47: 201-209, 1996.
161. Gusella JF, MacDonald ME. Pathogenic mechanism in Huntington's disease. Function and dysfunction in the nervous system. Cold Spring Harb Symp Quant Biol (in press).
162. Gutekunst C-A, Levey AI, Heilman CJ, Whaley WL, Yi H, Nash NR, Rees HD, Madden JJ, Hersch SM. Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies. Proc Natl Acad Sci U S A 92: 8710-8714, 1995.
163. Haerer AF, Currier RD, Jackson JF. Hereditary nonprogressive chorea of early onset. N Engl J Med 276: 1220-1224, 1967.
164. Hardie RJ. Acanthocytosis and neurological impairment - a review Q J Med 71: 291-306, 1989.
165. Harper PS. Benign hereditary chorea: Clinical and genetic aspects. Clin Genet 13: 85-95, 1978.
166. Harper PS. Huntington's disease. London: WB Saunders, 1996.
167. Harper PS. The epidemiology of Huntington's disease. Hum Genet 89: 365-376, 1992.
168. Harris GJ, Pearlson GD, Peyser CE, Aylward EH, Roberts J, Barta PE, Chase GA, Folstein SE. Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington disease. Ann Neurol 31: 69-75, 1992.
169. Harris GJ, Aylward EH, Peyser CE, Pearlson GD, Brandt J, Roberts-Twillie JV, Barta PE, Folstein SE. Single photon emission computed tomographic blood flow and magnetic resonance volume imaging of basal ganglia in Huntington's disease. Arch Neurol 53: 316-324, 1996.
170. Hayden MR. Huntington's chorea. Berlin: Springer-Verlag, 1981.
171. Hayden MR, Martin WRW, Stoessl AJ, Clark C, Hollenberg S, Adam MJ, Ammann W, Harrop R, Rogers J, Ruth T, Sayre C, Pate BD. Positron emission tomography in the early diagnosis of Huntington's disease Neurology 36: 888-894, 1986.
172. Hedreen JC, DeLong MR. Organization of striatopallidal, striatonigral, and nigrostriatal projections in the macaque. J Comp Neurol 304:569-595, 1991.
173. Hedreen JC, Peyser CE, Folstein SE, Ross CA. Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease. Neurosci Lett 133: 257-261, 1991.
174. Hedreen JC, Folstein SE. Early loss of neostriatal strisome neurons in Huntington's disease. J Neuropath Exp Neurol 54: 105-120, 1995.
175. Hedreen JC, Ross CA. Huntington's disease. In: The primary degenerative dementias other than Alzheimer's disease. Clark AW, Dickson DW, eds. Durham: Carolina Academic Press (in press).
176. Hein C, Springae J-V, Volland C, Haguenauer-Tsapis R, Andre B. NPL1, an essential gene involved in induced degradation of Gap1 and Fur4 permeases, encodes the Rsp5 ubiquitin-protein ligase. Mol Microbiol 18: 77-87, 1995.
177. Henshaw R, Jenkins BG, Schulz JB, Ferrante RJ, Kowall NW, Rosen BR, Beal MF. Malonate produces striatal lesions by indirect NMDA receptor activation. Brain Res 647: 161-166, 1994.
178. Higgins JJ, Nee LE, Vasconcelos O, Ide SE, Lavedan C, Goldfarb LG, Polymeropoulos MH. Mutations in American families with spinocerebellar ataxia (SCA) type 3: SCA3 is allelic to Machado-Joseph disease Neurology 46: 208-213, 1996.
179. Ho M, Chelly J, Carter N, Danek A, Crocker P, Monaco AP. Isolation of the gene for McLeod syndrome that encodes a novel membrane transport protein. Cell 77: 869-880, 1994.
180. Holtzman DA, Yang S, Drubin DG. Synthetic-lethal interactions identify two novel genes, SLA1 and SLA2, that control membrane cytoskelton assembly in Saccharomyces cerevisiae. J Cell Biol 122: 635-644, 1993
181. Hoogeveen AT, Willemsen R, Meyer N, de Rooij KE, Roos RAC, van Ommen G-JB, Galjaard H. Characterization and localization of the Huntington disease gene product. Hum Mol Genet 2: 2069-2073, 1993.
182. Housman D. Gain of glutamines, gain of function? Nat Genet 10: 3-4 1995.
183. Huibregste JM, Scheffner M, Beaudenon S, Howley PM. A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase. Proc Natl Acad Sci U S A 92: 2563-2567, 1995.
184. Huntington Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72: 971-983, 1993.
185. Huntington G. On chorea Med Surg Reporter Philadelphia 26: 317-321, 1872.
186. Huntington G. Recollections of Huntington's chorea as I saw it at East Hampton, Long Island, during my boyhood. J Nerv Ment Dis 37: 255, 1910.
187. Huntington Study Group. Unified Huntington's disease rating scale: Reliability and consistency. Mov Disord 11: 136-142, 1996.
188. Ichinose H, Ohye T, Takahashi E, Seki N, Hori T, Segawa M, Nomura Y, Endo K, Tanaka H, Tsuji S, Fujita K, Nagatsu T. Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene. Nat Genet 8: 236-241, 1994.
189. Iizuka R, Hirayama K, Maehara K. Dentato-rubro-pallido-luysian atrophy: A clinico-pathological study. J Neurol Neurosurg Psychiatry 47: 1288-1298, 1984.
190. Ikeda H, Yamaguchi M, Sugai S, Aze Y, Narumiya S, Kakizuka A. Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo. Nat Genet 13: 196-202, 1996.
191. Ikeuchi T, Koide R, Tanaka H, Onodera O, Igarashi S, Takahashi H, Kondo R, Ishikawa A, Tomoda A, Miike T, Sato K, Ihara Y, Hayabara T, Isa F, Tanabe H, Tokiguchi S, Hayashi M, Isa F, Tanabe H, Tokiguchi S, Hayashi M, Shimizu N, Ikuta F, Naito H, Tsuji S. Dentatorubral-pallidoluysian atrophy: Clinical features are closely related to unstable expansions of trinucleotide (CAG) repeat. Ann Neurol 37: 769-775, 1995.
192. Ikeuchi T, Onodera O, Oyake M, Koide R, Tanaka H, Tsugi S. Dentatorubro-pallidoluysian atrophy (DRPLA): Close correlation of CAG repeat expansions with the wide spectrum of clincal presentations and prominent anticipation. Semin Cell Biol 6: 37-44, 1995.
193. Illarioshkin SN, Igarashi S, Onodera O, Markova ED, Nikolskaya NN, Tanaka H, Chabrashwili TZ, Insarova NG, Endo K, Ivanova-Smolenskaya IA, Tsuji S. Trinucleotide repeat length and rate of progression of Huntington's disease. Ann Neurol 36: 630-635, 1994.
194. 2-weighted MRI signals in the globus pallidus in juvenile-type of dentatorubral and pallidoluysian atrophy. Neuropediatrics 25: 234-237, 1994.
195. Imbert G, Kretz C, Johnson K, Mandel JL, Origin of the expansion mutation in myotonic dystrophy. Nat Genet 4: 72-76, 1993.
196. Imbert G, Saudou F, Yvert G, Devys D, Trottier Y, Gamier J-M, Weber C, Mandel J-L (Group 1), Cancel G, Abbas N, Dürr A, Didierjean O, Stevanin, Agid Y, Brice A (Group 2). Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat Genet 14: 295-296, 1996.
197. International Batten Disease Consortium. Isolation of a novel gene underlying Batten disease, CLN3. Cell 82: 949-957, 1995.
198. Irani K, Xia Y, Zwieer JL, Sollott SJ, Der CJ, Fearon ER, Sundaresan M, Finkel T, Goldschmidt-Clemont PJ. Mitogenic signaling mediated by oxidants in ras-transformed fibroblasts. Science 275: 1649-1652, 1997.
199. Ishitani R, Sunaga K, Hirano A, Saunders P, Katsube N, Chuang D-M. Evidence that glyceraldehyde-3-phosphate dehydrogenase is involved in age-induced apoptosis in mature cerebellar neurons in culture. J Neurochem 66: 928-935, 1996.
200. Jackson M, Gentleman S, Lennox G, Ward L, Gray T, Randall K, Morrell XK, Lowe J. The cortical neuritic pathology of Huntington's disease. Neuropathol Appl Neurobiol 21: 18-26, 1995.
201. Jacobson MD, Weil M, Raff MC. Programmed cell death in animal development. Cell 88: 347-354, 1997.
202. Jankovic J, Ashizawa T. Tourettism associated with Huntington's disease. Mov Disord 10: 103-105, 1995.
203. Jenkins B, Koroshetz W, Beal MF, Rosen B. Evidence for an energy metabolism defect in Huntington's disease using localized proton spectroscopy. Neurology 43: 2689-2695, 1993.
204. Jenkins BG, Brouillet E, Chen Y-CI, Storey E, Schulz JB, Kirschner P, Beal MF, Rosen BR. Non-invasive neurochemical analysis of focal excitotoxic lesions in models of neurodegenerative illness using spectroscopic imaging. J Cereb Blood Flow Metab 16: 450-461, 1996.
205. Jensen P, Sørensen SA, Fenger K, Bolwig TG. A study of psychiatric morbidity in patients with Huntington's disease, their relatives, and controls. Admissions to psychiatric hospitals in Denmark from 1969 to 1991. Br J Psychiatry 163: 790-797, 1993.
206. Jeste DV, Barban L, Parisi J. Reduced Purkinje cell density in Huntington's disease. Exp Neurol 85: 78-86, 1984.
207. Jodice C, Malaspina P, Persichetti F, Novelletto A, Spadaro M, Giunti P, Morocutti C, Terrenato L, Harding AE, Frontali M. Effect of trinucleotide repeat length and parental sex on phenotypic variation in spinocerebellar ataxia 1. Am J Hum Genet 54: 959-965, 1994.
208. Jou Y-S, Myers RM. Evidence from antibody studies that the CAG repeat in the Huntington disease gene is expressed in the protein. Hum Mol Genet 4: 465-469, 1995.
209. Junck L, Fink JK. Machado-Joseph disease and SCA3: The genotype meets the phenotypes. Neurology 46: 4-8, 1996.
210. Kalchman MA, Graham RK, Xia G, Koide HB, Hodgson JG, Graham KC, Goldberg YP, Gietz RD, Pickart CM, Hayden MR. Huntingtin is ubiquitinated and interacts with a specific ubiquitin conjugated enzyme. J Biol Chem 271: 19385-19394, 1996.
211. Kang S, Jaworski A, Ohshima K, Wells RD. Expansion and deletion of CTG repeats from human disease genes are determined by the direction of replication in E. coli. Nat Genet 10: 213-218, 1995.
212. Karlin S, Burge C. Trinucleotide repeats and long homopeptides in genes and proteins associated with nervous system disease and development. Proc Natl Acad Sci U S A 93: 1560-1565, 1996.
213. Kartsounis LD, Hardie RJ. The pattern of cognitive impairments in neuroacanthocytosis. A frontal subcortical dementia. Arch Neurol 53: 77-80, 1996.
214. Kawaguchi Y, Okamoto T, Taniwaki M, Aizawa M, Inoue M, Katayama S, Kawakami H, Nakamura S, Nishimura M, Akiguchi I, Kimura J, Narumiya S, Kakizuka A. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet 8: 221-228, 1994.
215. Kawakami H, Maruyama H, Nakamura S, Kawaguchi Y, Kakizuka A, Doyu M, Sobue G. Unique features of the CAG repeats in Machado-Joseph disease. Nat Genet 9: 344-345, 1995.
216. Khan FA, Margolis RL, Loev SL, Sharp AH, Li S-H, Ross CA. cDNA cloning and characterization of an atrophin-1 (DRPLA disease gene)-related protein. Neurobiol Dis 3: 121-128, 1996.
217. Kieburtz K, MacDonald M, Shih C, Feigin A, Steinberg K, Bordwell K, Zimmerman C, Srinidhi J, Sotack J, Gusella J, Shoulson I. Trinucleotide repeat length and progression of illness in Huntington's disease. J Med Genet 31: 872-874, 1994.
218. Kieburtz K, Feigin A, McDermott M, Como P, Abwender D, Zimmerman C, Hickey C, Orme C, Claude K, Sotack J, Greenamyre JT, Dunn C, Shoulson I. A controlled trial of remacemide hydrochloride in Huntington's disease. Mov Disord 11: 273-277, 1996.
219. + toxicity and oxidative stress in neonatal animals. Brain Res 713: 178-185, 1996.
220. Knight SP, Richardson MM, Osmand AP, Stakkestad A, Potter NT. Expression and distribution of the dentatorubral-pallidoluysian atrophy gene product (atrophin-1/drplap) in neuronal and non-neuronal tissues. J Neurolog Sci 146: 19-26, 1997.
221. Koide R, Ikeuchi T, Onodera O, Tanaka H, Igarashi S, Endo K, Takahashi H, Kondo R, Ishikawa A, Hayashi T, Tomoda A, Miike T, Naito H, Ikuta F, Tsuji S. Unstable expansion of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DRPLA). Nat Genet 6: 9-13, 1994.
222. Komure O, Sano A, Nishino N, Yamauchi N, Ueno S, Kondoh K, Sano N, Takahashi M, Murayama N, Kondo I, Nagafuchi S, Yamada M, Kanazawa I. DNA analysis in hereditary dentatorubral-pallidoluysian atrophy: Correlation between CAG repeat length and phenotypic variation and the molecular basis of anticipation. Neurology 45: 143-149, 1995.
223. Kondo I, Ohta H, Yazaki M, Ikeda J-E, Gusella JF, Kanazawa I. Exclusion mapping of the hereditary dentatorubropallidoluysian atrophy gene from the Huntington's disease locus. J Med Genet 27: 105-108, 1990.
224. 10. Ann Neurol 41: 160-165, 1997.
225. Koshy B, Matilla T, Burright EN, Merry DE, Fischbeck KH, Orr HT, Zoghbi HY. Spinocerebellar ataxia type-1 and spinobulbar muscular atrophy gene products interact with glyceraldehyde-3-phosphate dehydrogenase. Hum Mol Genet 5: 1311-1318, 1996.
226. Kowall NW, Ferrante RJ, Martin JB. Patterns of cell loss in Huntington's disease. Trends Neurosci 10: 24-29, 1987.
227. Kremer B, Squitieri F, Telenius H, Andrew SE, Theilmann J, Spence N, Goldberg YP, Hayden MR. Molecular analysis of late onset Huntington's disease. J Med Genet 30: 991-995, 1993.
228. Kremer B, Goldberg P, Andrew SE, Theilmann J, Telenius H, Zeisler J, Squitieri F, Lin B, Bassett A, Almqvist E, Bird TD, Hayden MR. A worldwide study of the Huntington's disease mutation: The sensitivity and specificity of measuring CAG repeats. N Engl J Med 330: 1410-1416, 1994.
229. Kremer B, Almqvist E, Theilmann J, Spence N, Telenius H, Goldberg YP, Hayden MR. Sex-dependent mechanisms for expansions and contractions of the CAG repeat on affected Huntington disease chromosomes. Am J Hum Genet 57: 343-350, 1995.
230. Kremer HPH, Roos RAC, Dingjan G, Marani E, Bots GTAM. Atrophy of the hypothalamic lateral tuberal nucleus in Huntington's disease. J Neuropathol Exp Neurol 49: 371-382, 1990.
231. Kristjansson K, Chong SS, Van den Veyver IB, Subramanian S, Snabes MC, Hughes MR. Preimplantation single cell analyses of dystrophin gene deletions using whole genome amplification. Nat Genet 6: 19-23, 1994.
232. Kuwert T, Lange HW, Langen KJ, Herzog H, Aulich A, Feinendegen LE. Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. Brain 113: 1405-1423, 1990.
233. Lafon-Cazal M, Pietri S, Culcasi M, Bockaert J. NMDA-dependent superoxide production and neurotoxicity. Nature 364: 535-537, 1993.
234. Lamaze C, Chuang T-H, Terlecky LJ, Bokoch GM, Schmid SL. Regulation of receptor-mediated endocytosis by Rho and Rac. Nature 382: 177-179, 1996.
235. Landwehrmeyer GB, McNeil SM, Dure LS IV, Ge P, Aizawa H, Huang Q, Ambrose CM, Duyao MP, Bird ED, Bonilla E, de Young M, Avila-Gonzales AJ, Wexler NS, DiFiglia M, Gusella JF, MacDonald ME, Penney JB, Young AB, Vonsattel J-P. Huntington's disease gene: Regional and cellular expression in brain of normal and affected individuals. Ann Neurol 37: 218-230, 1995.
236. Lange HW, Thörner G, Hopf A, Schröder KF. Morphometric studies of the neuropathological changes hi choreatic diseases. J Neurol Sci 28: 401-4125, 1976.
237. Lange HW. Quantitative changes of telencephalon, diencephalon, and mesencephalon in Huntington's chorea, post-encephalitic, and idiopathic parkinsonism. Verh Anat Ges 75: 923-925, 1981.
238. La Spada AR, Paulson HL, Fishbeck KH. Trinucleotide repeat expansion in neurological disease. Ann Neurol 36: 814-822, 1994.
239. Leeflang EP, Zhang L, Tavaré S, Hubert R, Srinidhi J, MacDonald ME, Myers RH, de Young M, Wexler NS, Gusella JF, Arnheim N. Single sperm analysis of the trinucleotide repeats in the Huntington's disease gene: Quantification of the mutation frequency spectrum. Hum Mol Genet 4: 1519-1526, 1995.
240. Leli DA, Furlow TW Jr, Falgout JC. Benign familial chorea: An association with intellectual impairment. J Neurol Neurosurg Psychiatry 47: 471-474, 1984.
241. U S-H, McInnis MG, Margolis RL, Antonarakis SE, Ross CA. Novel triplet repeat containing genes in human brain: Cloning, expression, and length polymorphisms. Genomics 16: 572-579, 1993.
242. Li S-H, Schilling G, Young WS III, Li XJ, Margolis RL, Stine OC, Wagster MV, Abbott MH, Franz ML, Ranen SE, Hedreen JC, Ross CA. Huntington's disease gene (IT-15) is widely expressed in human and rat tissues. Neuron 11: 985-993, 1993.
243. Li XJ, Li S-H, Sharp AH, Nucifora FC Jr, Schilling G, Lanahan A, Worley P, Snyder SH, Ross CA. A huntingtin-associated protein enriched in brain with implications for pathology. Nature 378: 398-402, 1995.
244. Li XJ, Sharp AH, Li S-H, Dawson TM, Snyder SH, Ross CA. Huntingtin-associated protein (HAP1): Discrete neuronal localizations in the brain resemble nitric oxide synthase. Proc Natl Acad Sci U S A 93: 4839-4844, 1996.
245. Lin B, Rommens JM, Graham RK, Kalchman M, MacDonald H, Nasir J, Delaney A, Goldberg YP, Hayden MR. Differential 3′ polyadenylation of the Huntington disease gene results in two mRNA species with variable tissue expression. Hum Mol Genet 2: 1541-1545, 1993.
246. Lin B, Nasir J, MacDonald H, Hutchinson G, Graham RK, Rommens JM, Hayden MR. Sequence of the murine Huntington disease gene: Evidence for conservation, alternate splicing and polymorphism in a triplet (CCG) repeat. Hum Mol Genet 3: 85-92, 1994.
247. Lin B, Nasir J, Kalchman MA, McDonald H, Zeisler J, Goldberg YP, Hayden MR. Structural analysis of the 5-prime region of mouse and human Huntington disease genes reveals conservation of putative promoter region and di- and trinucleotide polymorphisms. Genomics 25: 707-715, 1995.
248. Loev SJ, Margolis RL, Young WS, Li S-H, Schilling G, Ashworth RG, Ross CA. Cloning and expression of the rat atrophin-1 (DRPLA disease gene) homologue. Neurobiol Dis 2: 129-138, 1995.
249. López-Villegas D, Kulisevsky J, Deus J, Junqué C, Pujol J, Guardia E, Grau JM. Neuropsychological alterations in patients with computed tomography-detected basal ganglia calcification. Arch Neurol 53: 251-256, 1996.
250. MacDonald ME, Haines JL, Zimmer M, Cheng SV, Youngman S, Whaley WL, Wexler N, Bucan M, Allitto BA, Smith B, Leavitt J, Poustka A, Harper P, Lehrach H, Wasmuth JJ, Frischauf A-M, Gusella JF. Recombination events suggest potential sites for the Huntington's disease gene. Neuron 3: 183-190, 1989.
251. MacDonald ME, Lin C, Srinidhi L, Bates G, Altherr M, Whaley WL, Lehrach H, Wasmuth J, Gusella JF. Complex patterns of linkage disequilibrium in the Huntington disease region. J Hum Genet 49: 723-734, 1991.
252. MacDonald ME, Novelletto A, Lin C, Tagle D, Barnes G, Bates G, Taylor S, Allitto B, Altherr M, Myers R, Lehrach H, Collins FS, Wasmuth JJ, Frontali M, Gusella JF. The Huntington's disease candidate region exhibits many different haplotypes. Nat Genet 1: 99-103, 1992.
253. MacDonald ME, Barnes G, Srinidhi J, Duyao MP, Ambrose CM, Myers RH, Gray J, Conneally PM, Young A, Penney J, Shoulson I, Hollingsworth Z, Koroshetz W, Bird E, Vonsattell JP, Bonilla E, Moscowitz C, Penchaszadeh G, Brzustowicz L, Alvir J, Bickham Conde J, Cha J-H, Dure L, Gomez F, Ramos-Arroyo M, Sanchez-Ramos J, Snodgrass SR, de Young M, Wexler NS, MacFarlane H, Anderson MA, Jenkins B, Gusella JF. Gametic but not somatic instability of CAG repeat length in Huntington's disease. J Med Genet 30: 982-986, 1993.
254. MacDonald ME, Gusella JF. Huntington's disease: Translating a CAG repeat into a pathogenic mechanism. Curr Opin Neurobiol 6: 638-650, 1996.
255. MacKay DJG, Nobas CD, Hall A. The Rho's progress: A potential role during neuritogenesis for the Rho family of GTPases. Trends Neurosci 18: 496-501, 1995.
256. MacMillan JC, Snell RG, Tyler A, Houlihan GD, Fenton I, Cheadle JP, Lazarou LP, Shaw DJ, Harper PS. Molecular analysis and clinical correlations of the Huntington's disease mutation. Lancet 342: 954-58, 1993.
257. MacMillan JC, Morrison PJ, Nevin NC, Shaw DJ, Harper PS, Quarrell OWJ, Snell RG. Identification of an expanded CAG repeat in the Huntington's disease gene (IT15) in a family reported to have benign hereditary chorea. J Med Genet 30: 1012-1013, 1993.
258. MacMillan JC, Davies P, Harper PS. Molecular diagnostic analysis for Huntington's disease: A prospective evaluation. J Neurol Neurosurg Psychiatry 58: 496-498, 1995.
259. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, Bates GP. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87: 493-506, 1996.
260. Margolis RL, Li S-H, Young WS, Wagster MV, Stine OC, Kidwai AS, Ashworth RG, Ross CA. DRPLA gene (atrophin-1) sequence and mRNA expression in human brain. Mol Brain Res 36: 219-226, 1996.
261. Martin JB, Gusella JF. Huntington's disease: Pathogenesis and management. N Engl J Med 315: 1267-1276, 1986.
262. Mary V, Wahl F, Stutzmann JM. Effect of riluzole on quinolinate-induced neuronal damage in rats: Comparison with blockers of glutamatergic neurotransmission. Neurosci Lett 201: 92-96, 1995.
263. Masuda N, Goto J, Murayama N, Watanabe M, Kondo I, Kanazawa I. Analysis of triplet repeats in the huntingtin gene in Japanese families affected with Huntington's disease. J Med Genet 32: 701-705, 1995.
264. Matilla A, Koshy B, Cummings CJ, Isobe T, Orr HT, Zoghbi HY. The cerebellar leucine rich acidic nuclear protein (LANP) interacts with ataxin-1: Further insight into the pathogenesis of SCA1. Nature (in press).
265. Matthews RT, Ferrante RJ, Jenkins BG, Browne SE, Goetz K, Berger S, Chen Y-C, Beal MF. Iodoacetate produces striatal excitotoxic lesions. J Neurochem (in press).
266. Mayeux R, Stern Y, Herman A, Greenbaum L, Fahn S. Correlates of early disability in Huntington's disease. Ann Neurol 20: 727-731, 1986.
267. Mazziotta JC, Phelps ME, Pahl JJ, Huang S-C, Baxter LR, Riege WH, Hoffman JM, Kuhl DE, Lanto AB, Wapenski JA, Markham CH. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. N Engl J Med 316: 357-362, 1987.
268. McGeer EG, McGeer PL. Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids. Nature. 263: 517-9, 1976.
269. McHugh PR, Folstein MF. Psychiatric syndromes of Huntington's chorea: A clinical and phenomenological study. In: Benson DF, Blumer D, eds. Psychiatric aspects of neurologic disease. New York: Grune and Stratton, pp 267-286, 1975.
270. McKusick VA. Mendelian inheritance in man: A catalog of human genes and genetic disorders. 12th ed. Baltimore: Johns Hopkins University Press, 1997.
271. McNeil SM, Novelletto A, Srinidhi J, Barnes G, Kornbluth I, Altherr MR, Wasmuth JJ, Gusella JF, MacDonald ME, Myers RH. Reduced penetrance of the Huntington's disease mutation. Hum Mol Genet 6: 775-779, 1997.
272. Medalia A, Isaacs-Glaberman K, Scheinberg H. Neuropsychological impairment in Wilson's disease. Arch Neurol 45: 502-504, 1988.
273. Meissen GJ, Myers RH, Mastromauro CA, Koroshetz WJ, Klinger KW, Fairer LA, Watkins PA, Gusella JF, Bird ED, Martin JB. Predictive testing for Huntington's disease with use of a linked DNA marker. N Engl J Med 318: 535-542, 1988.
274. Miwa S. Triplet repeats strike again. Nat Genet 6: 3-4, 1994.
275. Miyazaki M, Hashimoto T, Yoneda Y, Tayama M, Harada M, Miyoshi H, Kawano N, Murayama N, Kondo I, Kuroda Y. Proton magnetic resonance spectroscopy on childhood-onset dentatorubral-pallidoluysian atrophy (DRPLA). Brain Dev 18: 142-146, 1996.
276. Morris MJ, Tyler A, Lazarou L, Meredith L, Harper PS. Problems in genetic prediction for Huntington's disease. Lancet 2: 601-603, 1989.
277. Morton NE, MacPherson JN. Population genetics of the fragile-X syndrome: Multiallelic model for the FMR1 locus. Proc Natl Acad Sci U S A 89: 4215-4217, 1992.
278. Muller DP, Lloyd JK, Wolff OH. Vitamin E and neurological function. Lancet 1: 225-228, 1983.
279. Myers RH, Madden JJ, Teague JL, Falek A. Factors related to onset age of Huntington disease. Am J Hum Genet 34: 481-488, 1982.
280. Myers RH, Cupples A, Schoenfeld M, D'Agostino RB, Terrin NC, Goldmakher N, Wolf PA. Maternal factors in onset of Huntington disease. Am J Hum Genet 37: 511-523, 1985.
281. Myers RH, Vonsattel J-P, Stevens TJ, Cupples LA, Richardson EP, Martin JB, Bird ED. Clinical and neuropathologic assessment of severity in Huntington's disease. Neurology 38: 341-347, 1988.
282. Myers RH, Leavitt J, Farrer LA, Jagadeesh J, McFarlane H, Mastromauro CA, Mark RJ, Gusella JF. Homozygote for Huntington disease. Am J Hum Genet 45: 615-618, 1989.
283. Myers RH, Sax DS, Koroshetz WJ, Mastromauro C, Cupples LA, Kiely DK, Pettengill FK, Bird ED. Factors associated with slow progression in Huntington's disease. Arch Neurol 48: 800-804, 1991.
284. n repeat in sporadic Huntington's disease. Nat Genet 5: 168-173, 1993.
285. Nagafuchi S, Yanagisawa H, Sato K, Shirayama T, Ohsaki E, Bundo M, Takeda T, Tadokoro K, Kondo I, Murayama N, Tanaka Y, Kikushima H, Umino K, Kurosawa H, Furukawa T, Nihei K, Inoue T, Sano A, Komure O, Takahashi M, Yoshizawa T, Kanazawa I, Yamada M. Dentatorubral and pallidoluysian atrophy expansion of an unstable CAG trinucleotide on chromosome 12p. Nat Genet 6: 14-18, 1994.
286. Nagafuchi S, Yanagisawa H, Ohsaki E, Shirayama T, Tadokoro K, Inoue T, Yamada M. Structure and expression of the gene responsible for the triplet repeat disorder, dentatorubral and pallidoluysian atrophy (DRPLA). Nat Genet 8: 177-182, 1994.
287. Nagata S. Apoptosis by death factor. Cell 88: 355-365, 1997.
288. Naito H, Oyanagi S. Familial myoclonus epilepsy and choreoathetosis: Hereditary dentatorubral-pallidoluysian atrophy. Neurology 32: 798-807, 1982.
289. Nakano KK, Dawson DM, Spence A. Machado disease. A herediatry ataxia in Portuguese emigrants to Massachusetts. Neurology 22: 49-55, 1972.
290. Nance MA. Huntington disease - another chapter rewritten. Am J Hum Genet 59: 1-6, 1996.
291. Nasir J, Lin B, Bucan M, Koizumi T, Nadeau JH, Hayden MR. The murine homologues of the Huntington disease gene (Hdh) and the α-Adducin gene (Add1) map to mouse chromosome 5 within a region of conserved synteny with human chromosome 4p16.3. Genomics 22: 198-201, 1994.
292. Nasir J, Floresco SB, Okusky JR, Diewert VM, Richman JM, Zeisler J, Borowski A, Marth JD, Phillips AG, Hayden MR. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 81: 811-823, 1995.
293. Nasir J, Goldberg YP, Hayden MR. Huntington disease: New insights into the relationship between CAG expansion and disease. Hum Mol Genet 5: 1431-1435, 1996.
294. Neville CE, Mahadeven MS, Barcelo JM, Korneluk RG. High resolution genetic analysis suggests on ancestral predisposing haplotype for the origin of the myotonic dystrophy mutation. Hum Mol Genet 3: 45-51, 1994.
295. Nicholl D, Windl O, de Silva R, Sawcer S, Dempster M, Ironside JW, Estibeiro JP, Yuill GM, Lathe R, Will RG. Inherited Creutzfeldt-Jakob disease in a British family associated with a novel 144 base pair insertion of the prion protein gene. J Neurol Neurosurg Psychiatry 58: 65-69, 1995.
296. Nishiyama K, Nakamura K, Murayama S, Yamada M, Kanazawa I. Regional and cellular expression of the dentatorubral-pallidoluysian atrophy gene in brains of normal and affected individuals. Ann Neurol 41: 599-605, 1997.
297. Norremolle A, Nielsen JE, Sorensen SA, Hasholt L. Elongated CAG repeats of the B37 gene in a Danish family with dentato-rubro-pallidoluysian atrophy. Hum Genet 95: 313-318, 1995.
298. Olanow CW. A radical hypothesis for neurodegeneration. Trends Neurosci 16: 439-444, 1993.
299. Onodera O, Oyake M, Takano H, Ikeuchi T, Igarashi S, Tsuji S. Molecular cloning of a full-length cDNA for dentatorubral-pallidoluysian atrophy and regional expressions of the expanded alleles in the CNS. Am J Hum Genet 57: 1050-1060, 1995.
300. Osier W. Remarks on the varieties of chronic chorea, and a report upon two families of the hereditary form, with one autopsy. J Nerv Ment Dis 18: 97-111, 1893.
301. Oyake M, Onodera O, Shiroishi T, Takano H, Takahashi Y, Kominami R, Moriwaki K, Ikeuchi T, Igarashi S, Tanaka H, Tsuji S. Molecular cloning of murine homologue dentatorubral-pallidoluysian atrophy (DRPLA) cDNA: Strong conservation of a polymorphic CAG repeat in the murine gene. Genomics 40: 205-207, 1997.
302. Palfi S, Ferrante RJ, Brouillet E, Beal MF, Dolan R, Guyot MC, Peschanski M, Hantraye P. Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease. J Neurosci 16: 3019-3025, 1996.
303. Palo J, Somer H, Ikonen E, Karila L, Peltonen L. Low prevalence of Huntington's disease in Finland. Lancet 1: 805-806, 1987.
304. Pang Z, Geddes JW. Mechanisms of cell death induced by the mitochondrial toxin 3-nitropropionic acid: Acute excitotoxic necrosis and delayed apoptosis. J Neurosci 17: 3064-3073, 1997.
305. Parrish JE, Nelson DL. Methods for finding genes: A major rate-limiting step in positional cloning. Genet Anal Tech Appl 10: 29-41, 1993.
306. Paulson HL, Fischbeck KH. Trinucleotide repeats in neurogenetic disorders. Annu Rev Neurosci 19: 79-107, 1996.
307. Paulson HL, Perez MK, Trottier Y, Trojanowski JQ, Subramony SH, Das SS, Vig P, Mandel J-L, Fischbeck KH, Pittman RN. Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron 19: 333-344, 1997.
308. Paulson JS, Butters N, Sadek JR, Johnson SA, Salmon DP, Swerdlow NR, Swenson MR. Distinct cognitive profiles of cortical and subcortical dementia in advanced illness. Neurology 45: 951-956, 1995.
309. Peiris JB, Boralessa H, Lionel NDW. Clonazepam in the treatment of choreiform activity. Med J Aust 1: 225-227, 1976.
310. Penney JB Jr, Young AB, Shoulson I, Starosta-Rubenstein S, Snodgrass SR, Sanchez-Ramos J, Ramos-Arroyo M, Gomez F, Penchaszadeh G, Alvir J, Esteves J, DeQuiroz I, Marsol N, Moreno H, Conneally PM, Bonilla E, Wexler NS. Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. Mov Disord 5: 93-99, 1990.
311. Penney JB Jr, Vonsattel J-P, MacDonald ME, Gusella JF, Myers RH. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol 41: 689-692, 1997.
312. Persichetti F, Srinidhi J, Kanaley L, Ge P, Myers RH, D'Arrigo K, Barnes GT, MacDonald ME, Vonsattel J-P, Gusella JF, Bird ED. Huntington's disease CAG trinucleotide repeats in pathologically confirmed postmortem brains. Neurobiol Dis 1: 159-166, 1994.
313. Persichetti F, Ambrose CM, Ge P, McNeil SM, Srinidhi J, Anderson MA, Jenkins B, Barnes GT, Duyao MP, Kanaley L, Wexler NS, Myers RH, Bird ED, Vonsattel J-P, MacDonald ME, Gusella JF. Normal and expanded Huntington's disease gene alleles produce distinguishable proteins due to translation across the CAG repeat. Mol Med 1: 374-383, 1995.
314. Persichetti F, Carlee L, Faber PW, McNeil SM, Ambrose CM, Srinidhi J, Anderson MA, Barnes GT, Gusella JF, MacDonald ME. Differential expression of normal and mutant Huntington's disease gene alleles. Neurobiol Dis 3: 183-190, 1996.
315. Perutz M. Polar zippers: Their role in human disease. Protein Sci 3: 1629-1637, 1994.
316. Peyser CE, Folstein SE. Huntington's disease as a model for mood disorders: Clues from neuropathology and neurochemisty. Mol Chem Neuropathol 12: 99-119, 1990.
317. Peyser CE, Folstein MF, Chase GA, Starkstein S, Brandt J, Cockrell JR, Bylsma F, Coyle JT, McHugh PR, Folstein SE. Trial of d-alpha-Tocopherol in Huntington's disease. Am J Psychiatry 152: 1771-1775, 1995.
318. Pillon B, Blin J, Vidailhet M, Deweer B, Sirigu A, Dubois B, Agid Y. The neuropsychological pattern of corticobasal degeneration: Comparison with progressive supranuclear palsy and Alzheimer's disease. Neurology 45: 1477-1483, 1995.
319. Pillon B, Dubois B, Agid Y. Testing cognition may contribute to the diagnosis of movement disorders. Neurology 46: 329-334, 1996.
320. Portera-Cailliau C, Hedreen JC, Price DL, Koliatsos VE. Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models. J Neurosci 15: 3775-3787, 1995.
321. Potter NT, Meyer MA, Zinunerman AW, Eisenstadt ML, Anderson IJ. Molecular and clinical findings in a family with dentatorubral-pallidoluysian atrophy. Ann Neurol 37: 273-277, 1995.
322. Primmer CR, Ellegren H, Saino N, Moller AP. Directional evolution in germline microsatellite mutations. Nat Genet 13: 391-393, 1996.
323. Pritchard C, Zhu N, Zuo J, Bull L, Pericak-Vance MA, Vance JM, Roses AD, Milatovich A, Francke U, Cox DR, Myers RM. Recombination of 4p16 DNA markers in an unusual family with Huntington's disease. Am J Hum Genet 50: 1218-1230, 1992.
324. Pulst S-M, Nechiporuk A, Nechiporuk T, Gispert S, Chen X-N, Lopes-Cendes I, Pearlman S, Starkman S, Orozco-Diaz G, Lunkes A, DeJong P, Rouleau GA, Auburger G, Korenberg JR, Figueroa C, Sahba S. Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat Genet 14: 209-276, 1996.
325. Quaid KS, Morris M. Reluctance to undergo predictive testing: The case of Huntington's disease. Am J Med Genet 45: 41-45, 1993.
326. Quarrell OW, Youngman S, Sarfarazi M, Harper PS. Absence of close linkage between benign hereditary chorea and the locus D4S10 (probe G8). J Med Genet 25: 191-194, 1988.
327. Ranen NG, Peyser CE, Folstein SE. A physician's guide to the management of Huntington's disease: Pharmacologic and non-pharmacologic alternatives. New York: HDSA, 1993.
328. Ranen NG, Peyser CE, Folstein SE. ECT treatment of depression in Huntington's disease. J Neuropsychiatry Clin Neurosci 6: 154-159, 1994.
329. Ranen NG, Stine OC, Abbott MH, Sherr M, Codori A-M, Franz ML, Chao NI, Chung AS, Pleasant N, Callahan C, Chase GA, Brandt J, Folstein SE, Ross CA. Anticipation and instability of (CAG)n repeats in IT-15 in parent-offspring pairs with Huntington's disease. Am J Hum Genet 57: 593-602, 1995.
330. Ranen NG, Peyser CE, Coyle J, Bylsma F, Sherr M, Day L, Folstein MF, Brandt J, Ross CA, Folstein SE. A controlled trial of idebenone in Huntington's disease. Mov Disord 11: 549-554, 1996.
331. Ranen NG, Lipsey JR, Treisman G, Ross CA. Sertraline in the treatment of severe aggressiveness in Huntington's disease. J Neuropsychiatry Clin Neurosci 8: 338-340, 1996.
332. Ranum LPW, Chung M-Y, Banfi S, Bryer A, Schut LJ, Ramesar R, Duvick LA, McCall A, Subramony SH, Goldfarb L, Gomez C, Sandkuijl LA, Orr HT, Zoghbi HY. Molecular and clinical correlations in spinocerebellar ataxia type 1: Evidence for familial effects on the age at onset. Am J Hum Genet 55: 244-252, 1994.
333. Read AP. Huntington's disease: Testing the test. Nat Genet 4: 329-330, 1993.
334. Rees DJG, Ades SE, Singer SJ, Hynes RO. Sequence and domain structure of talin. Nature 347: 685-689, 1990.
335. Reik W. Genomic imprinting: A possible mechanism for the parental origin effect in Huntington's chorea. J Med Genet 25: 805-808, 1988.
336. Reiner A, Albin RL, Anderson KD, D'Amato CJ, Penney JB, Young AB. Differential loss of striatal projection neurons in Huntington's disease. Proc Natl Acad Sci U S A 5: 5733-5737, 1988.
337. Ridley RM, Frith CD, Crow TJ, Conneally PM. Anticipation in Huntington's disease is inherited through the male line but may originate in the female. J Med Genet 25: 589-595, 1988.
338. Ridley RM, Frith CD, Farrer LA, Conneally PM. Patterns of inheritance of the symptoms of Huntington's disease suggestive of an effect of genomic imprinting. J Med Genet 28: 224-231, 1991.
339. Robitaille Y, Lopes-Cendes, Becher M, Rouleau G, Clark AW. The neuropathology of CAG repeat diseases: Review and update of genetic and molecular features. Brain Pathol 7: 901-926, 1997.
340. Rodda RA. Cerebellar atrophy in Huntington's disease. J Neurolog Sci 50: 147-157, 1981.
341. Roos RAC, Hermans J, Vegter-van der Vlis M, van Ommen GJB, Bruyn GW. Duration of illness in Huntington's disease is not related to age at onset. J Neurol Neurosurg Psychiatry 56: 98-100, 1993.
342. Rosen A. Huntingtin: New marker along the road to death? Nat Genet 13: 380-382.
343. Rosenow F, Herholz K, Lanfermann H, Weuthen G, Ebner R, Kessler J, Ghaemi M, Heiss W-D. Neurological sequelae of cyanide intoxication-the patterns of clinical, magnetic resonance imaging, and positron emission tomography findings. Ann Neurol 38: 825-828, 1995.
344. Ross CA, McInnis MG, Margolis RL, Li S-H. Genes with triplet repeats: Candidate mediators of neuropsychiatric disorders. Trends Neurosci 16: 254-260, 1993.
345. Ross CA. When more is less: Pathogenesis of glutamine repeat neurodegenerative diseases. Neuron 15: 493-496, 1995.
346. Ross CA, Becher MW, Colomer V, Engelender S, Wood JD, Sharp AH. Huntington's disease and DRPLA: Proteins, pathogenesis, and pathology. Brain Pathol 7: 1003-1016, 1997.
347. Rothstein JD, Jin L, Dykes-Hoberg M, Kuncl RW. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc Natl Acad Sci U S A 90: 6591-6595, 1993.
348. Rubinsztein DC, Barton DE, Davison BCC, Ferguson-Smith MA. Analysis of the huntingtin gene reveals a trinucleotide-length polymorphism in the region of the gene that contains two CCG-rich stretches and a correlation between decreased age of onset of Huntington's disease and CAG repeat number. Hum Mol Genet 2: 1713-1715, 1993.
349. Rubinsztein DC, Amos W, Leggo J, Goodbum S, Ramesar RS, Old J, Bontrop R, McMahon R, Barton DE, Ferguson-Smith MA, Mutational bias provides a model for the evolution of Huntington's disease and predicts a general increase in disease prevalence. Nat Genet 7: 525-530, 1994.
350. n polymorphisms in the Huntington's disease (HD) gene provides an explanation for an apparent 'founder' HD haplotype. Hum Mol Genet 4: 203-206, 1995.
351. Rubinsztein DC, Amos W, Leggo J, Goodburn S, Jain S, Li S-H, Margolis RL, Ross CA, Ferguson-Smith MA. Microsatellites are generally longer in humans compared to their homologues in non-human primates: Evidence for directional evolution at microsatelite loci. Nat Genet 10: 337-343, 1995.
352. Rubinsztein DC, Leggo J, Coles R, Almqvist E, Biancalana V, Cassiman J-J, Chotai K, Connarty M, Craufurd D, Curtis A, Curtis D, Davidson MJ, Differ A-M, Dode C, Dodge A, Frontali M, Ranen NG, Stine OC, Sherr M, Abbott MH, Franz ML, Graham CA, Harper PS, Hedreen JC, Jackson A, Kaplan J-C, Losekoot M, MacMillan JC, Morrison P, Trottier Y, Novelletto A, Simpson SA, Theilmann J, Whittaker JL, Folstein SE, Ross CA, Hayden MR. Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats. Am J Hum Genet 59: 16-22, 1996.
353. Rubinsztein DC, Leggo J, Chiano M, Dodge A, Norbury G, Rosser E, Craufurd D. Genotypes at the GluR6 kainate receptor locus are associated with variation in the age of onset of Huntington disease. Proc Natl Acad Sci U S A 94: 3872-3876, 1997.
354. Sano A, Yamauchi N, Kakimoto Y, Komure O, Kawai J, Hazama F, Kuzume K, Sano N, Kondo I. Anticipation in hereditary dentatorubral-pallidoluysian atrophy. Hum Genet 93: 699-702, 1994.
355. Sanpei K, Takano H, Igarashi S, Sato T, Oyake M, Sasaki H, Wakisaka A, Tashiro K, Ishida Y, Ikeuchi T, Koide R, Saito M, Sato A, Tanaka T, Hanyu S, Takiyama Y, Nishizawa M, Shimizu N, Nomura Y, Segawa M, Kwabuchi K, Eguchi I, Tanaka H, Takahashi H, Tsuji S. Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT. Nat Genet 14: 277-284, 1996.
356. Sapp E, Schwarz C, Chase K, Bhide PG, Young AB, Penney J, Vonsattel JP, Aronin N, DiFiglia M. Huntingtin localizations in brains of normal and Huntington's disease patients. Ann Neurol (in press).
357. Sato K, Kashihara K, Okada S, Ikeuchi T, Tsuji S, Shomori T, Morimoto K, Hayabara T. Does homozygosity advance the onset of dentatorubral-pallidoluysian atrophy? Neurology 45: 1934-1936, 1995.
358. Scherzinger E, Lurz R, Turmaine M, Mangiarini L, Hollenbach B, Hasenbank R, Bates GP, Davies SW, Lehrach H, Wanker EE. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 90: 549-558, 1997.
359. Schilling G, Sharp AH, Loev SJ, Wagster MV, Li S-H, Stine OC, Ross CA. Expression of the Huntington's disease (IT15) protein product in HD patients. Hum Mol Genet 4: 1365-1371, 1995.
360. Schlötterer C, Tautz D. Slippage synthesis of simple sequence DNA. Nucleic Acids Res 20: 211-215, 1992.
361. Schmitt I, Bächner D, Megow D, Henklein P, Hameister H, Epplen JT, Riess O. Expression of the Huntington disease gene in rodents: Cloning the rat homologue and evidence for downregulation in non-neuronal tissues during development. Hum Mol Genet 4: 1173-1182, 1995.
362. Schmitt I, Epplen JT, Riess O. Predominant neuronal expression of the gene responsible for dentatorubral-pallidoluysian atrophy (DRPLA) in rat. Hum Mol Genet 4: 1619-1624, 1995.
363. Schoenfeld M, Myers RM, Cupples A, Berkman B, Sax DS, Clark E. Increased rate of suicide among patients with Huntington's disease. J Neurol Neurosurg Psychiatry 47: 1283-1287, 1984.
364. Schretlen D, Brandt J, Bobholz JH. Validation of the Brief Test of Attention in patients with Huntington's disease and amnesia. Clin Neuropsychologist 10: 90-95, 1996.
365. Schubert D, Kimura H, Maher P. Growth factors and vitamin E modify neuronal glutamate toxicity. Proc Natl Acad Sci U S A 89: 8264-8267 1992.
366. Schulman JD, Black SH, Handyside A, Nance WE. Preimplantation genetic testing for Huntington disease and certain other dominantly inherited disorders. Clin Genet 49: 57-58, 1996.
367. Schulz JB, Henshaw DR, Siwek D, Jenkins BG, Ferrante RJ, Cipolloni PB, Kowall NW, Rosen BR, Beal MF. Involvement of free radicals in excitotoxicity in vivo. J Neurochem 64: 2239-2247, 1995.
368. Schulz JB, Matthews RT, Jenkins BG, Ferrante RJ, Siwek D, Henshaw DR, Cipolloni PB, Mecocci P, Kowal NW, Rosen BR, Beal MF. Blockade of neuronal nitric oxide synthase protects against excitotoxicity in vivo. J Neurosci 15: 8419-8429, 1995.
369. Schulz JB, Huang PL, Matthews RT, Passov D, Fishman MC, Beal MF. Striatal malonate lesions are attenuated in neuronal nitric oxide synthase knockout mice. J Neurochem 67: 430-433, 1996.
370. Schweitzer JK, Livingstone DM. Destabilization of CAG trinucleotide repeat tracts by mismatch repair mutations in yeast. Hum Mol Genet 6: 349-355, 1997.
371. Sharp AH, Loev SJ, Schilling G, Li S-H, Li X-J, Bao J, Wagster MV, Kotzuk JA, Steiner JP, Lo A, Hedreen J, Sisodia S, Snyder SH, Dawson TM, Ryugo DK, Ross CA. Widespread expression of Huntington's disease gene (IT15) protein product. Neuron 14: 1065-1074, 1995.
372. Sharp AH, Ross CA. Neurobiology of Huntington's disease. Neurobiol Dis 3: 3-15, 1996.
373. Shibasaki H, Sakai T, Nishimura H, Sata Y, Goto I, Kuroiwa Y. Involuntary movements in chorea-acanthocytosis: A comparison with Huntington's chorea. Ann Neurol 12: 311-314, 1982.
374. Shoffner JM, Brown MD, Stugard C, Jun AS, Pollock S, Haas RH, Kaufman A, Koontz D, Kim Y, Graham JR, Smith E, Dixon J, Wallace DC. Leber's hereditary optic neuropathy plus dystonia is caused by a mitochondrial DNA point mutation. Ann Neurol 38: 163-169, 1995.
375. Shoulson I. Huntington disease: Functional capacities in patients treated with neuroleptic and antidepressant drugs. Neurology 31: 1333-1335, 1981.
376. Shoulson I, Odoroff C, Oakes D, et al. A controlled clinical trial of baclofen as protective therapy in early Huntington's disease. Ann Neurol 25: 252-259, 1989.
377. Shoulson I. Huntington's disease: Cognitive and psychiatric features. Neuropsychiatry Neuropsychology Behav Neurol 3: 15-22, 1990.
378. Silveira I, Lopes-Cendes I, Kish S, Maciel P, Gaspar C, Coutinho P, Botez MI, Teive H, Arruda W, Steiner CE, Pinto-Junior W, Maciel JA, Jain S, Sack G, Andermann E, Sudarsky L, Rosenberg R, MacLeod P, Chitayat D, Babul R, Sequeiros J, Rouleau GA. Frequency of spinocerebellar ataxia type 1, dentatorubropallidoluysian atrophy, and Machado-Joseph disease mutations in a large group of spinocerebellar ataxia patients. Neurology 46: 214-218, 1996.
379. Skinner PJ, Koshy B, Cummings CJ, Klement IA, Helin K, Servadio A, Zoghbi HY, Orr, HT. SCA1 pathogenesis involves alterations in nuclear matrix-associated structures. Nature (in press).
380. Smith B, Skarecky D, Bengtsson U, Magenis RE, Carpenter N, Wasmuth JJ. Isolation of DNA markers in the direction of the Huntington disease gene from the G8 locus. Am J Hum Genet 42: 335-344, 1988.
381. Smith JK, Gonda VE, Malamud N. Unusual form of cerebellar ataxia. Neurology 8: 205-209, 1958.
382. Smith JK. Dentatorubropallidoluysian atrophy. In: Vinken PJ, Bruyn GW, eds. Handbook of clinical neurology. New York: Elsevier 21: 519-534, 1975.
383. Smits MG, Gabreëls FJM, Thijssen HOM, 't Lam RL, Notermans SLH, ter Haar BGA, Prick JJ. Progressive idiopathic strio-pallido-dentate calcinosis (Fahr's disease) with autosomal recessive inheritance. Eur Neurol 22: 58-64, 1983.
384. Snell RG, Thompson LM, Tagle DA, Holloway TL, Barnes G, Harley HG, Sandkiüjl LA, MacDonald ME, Collins FS, Gusella JF, Harper PS, Shaw DJ. A recombination event that redefines the Huntington disease region. Am J Hum Genet 51: 357-362, 1992.
385. Snell RG, MacMillan JC, Cheadle JP, Fenton I, Lazarou LP, Davies P, MacDonald ME, Gusella JF, Harper PS, Shaw DJ. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat Genet 4: 393-397, 1993.
386. Sotrel A, Paskevich PA, Kiely DK, Bird ED, Williams RS, Myers RH. Morphometric analysis of the prefrontal cortex in Huntington's disease. Neurology 41: 1117-1123, 1991.
387. Sotrel A, Williams RS, Kaufmann WE, Myers RH. Evidence for neuronal degeneration and dendritic plasticity in cortical pyramidal neurons of Huntington's disease: A quantitative Golgi study. Neurology 43: 2088-2096, 1993.
388. Sprengelmeyer H, Lange H, Hömberg V. The pattern of attentional deficits in Huntington's disease. Brain 118: 145-152, 1995.
389. Squitieri F, Andrew SE, Goldberg YP, Kremer B, Spence N, Zeisler J, Nichol K, Theilmann J, Greenberg J, Goto J, Kanazawa I, Vesa J, Peltonen L, Almqvist E, Anvret M, Telenius H, Lin B, Napolitano G, Morgan K, Hayden MR. DNA haplotype analysis of Huntington disease reveals clues to the origins and mechanisms of CAG expansion and reasons for geographic variations of prevalence. Hum Mol Genet 3: 2103-2114, 1994.
390. Stine OC, Pleasant N, Franz ML, Abbott MH, Folstein SE, Ross CA. Correlation between the onset age of Huntington's disease and length of the trinucleotide repeat in IT-15. Hum Mol Genet 2: 1547-1549, 1993.
391. Stine OC, Li S-H, Pleasant N, Wagster MV, Hedreen JC, Ross CA. Expression of the mutant allele of IT-15 (the HD gene) in striatum and cortex of Huntington's disease patients. Hum Mol Genet 4: 15-18, 1995.
392. Stott K, Blackburn JM, Butler PJG, Perutz M. Incorporation of glutamine repeats makes protein cligomerize: Implications for neurodegenerative diseases. Proc Natl Acad Sci U S A 92: 6509-6513, 1995.
393. Strong TV, Tagle DA, Valdes JM, Elmer LW, Boehm K, Swaroop M, Kaatz KW, Collins FS, Albin RL. Widespread expression of the human and rat Huntington's disease gene in brain and nonneuronal tissues. Nat Genet 5: 259-265, 1993.
394. Sudarsky L, Myers RH, Walshe TM. Huntington's disease in monozygotic twins reared apart. J Med Genet 20: 408-411, 1983.
395. Sutherland GR, Richards RI. Simple tandem DNA repeats and human genetic disease. Proc Natl Acad Sci U S A 92: 3636-3641, 1995.
396. Sutherland GR, Richards RI. The molecular basis of fragile sites in human chromosomes. Curr Opin Genet Dev 5: 323-327, 1995.
397. Takahashi H, Ohama E, Naito H, Takeda S, Nakashima S, Makifuchi T, Ikuta F. Hereditary dentatorubral-pallidoluysian atrophy: Clinical and pathologic variants in a family. Neurology 38: 1065-1070, 1988.
398. Takano H, Onondera O, Takahashi H, Igarashi S, Yamada M, Oyake M, Ikeuchi T, Koide R, Tanaka H, Iwabuchi K, Tsuji S. Somatic mosaicism of expanded CAG repeats in brains of patients with dentatorubral-pallidoluysian atrophy: Cellular population-dependent dynamics of mitotic instability. Am J Hum Genet 58: 1212-1222, 1996.
399. Takiyama Y, Nishizawa M, Tanaka H, Kawashima S, Sakamoto H, Karube Y, Shimazaki H, Soutome M, Endo K, Ohta S, Kagawa Y, Kanazawa I, Mizuno Y, Yoshida M, Yuasa T, Horikawa Y, Oyanagi K, Nagai H, Kondo T, Inuzuka T, Onodera O, Tsuji S. The gene for Machado-Joseph disease maps to human chromosome 14q. Nat Genet 4: 300-306, 1993.
400. Takiyama Y, Oyanagi S, Kawashima S, Sakamoto H, Saito K, Yoshida M, Tsuji S, Mizuno Y, Nishizawa M. A clinical and pathologic study of a large Japanese family with Machado-Joseph disease tightly linked to the DNA markers on chromosome 14q. Neurology 44: 1302-1308, 1994.
401. Tanzi RE, Petrukhin K, Chernov I, Pellequer JL, Wasco W, Ross B, Romano DM, Parano E, Pavone L, Brzustowicz LM, Devoto M, Peppercorn J, Bush AI, Sternlieb I, Pirastu M, Gusella JF, Evgrafov O, Penchaszadeh GK, Honig B, Edelman IS, Scares MB, Scheinberg IH, Gillam TC. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat Genet 5: 344-350, 1993.
402. Taylor SAM, Snell RG, Buckler A, Ambrose C, Duyao M, Church D, Lin CS, Altherr M, Bates GP, Groot N, Barnes G, Shaw DJ, Lehrach H, Wasmuth JJ, Harper PS, Housman DE, MacDonald ME, Gusella JF. Cloning of the α-adducin gene from the Huntington's disease candidate region of chromosome 4 by exon amplification. Nat Genet 2: 223-227, 1992.
403. Telenius H, Kremer HPH, Theilmann J, Andrew SE, Almqvist E, Anvret M, Greenberg C, Greenberg J, Lucotte G, Squitieri F, Starr E, Goldberg YP, Hayden MR. Molecular analysis of juvenile Huntington disease: The major influence on (CAG)n repeat length is the sex of the affected parent. Hum Mol Genet 2: 1535-1540, 1993.
404. Telenius H, Kremer B, Goldberg YP, Theilmann J, Andrew SE, Zeisler J, Adam S, Greenberg C, Ives EJ, Clarke LA, Hayden MR. Somatic and gonadal mosaicism of the Huntington disease gene CAG repeat in brain and sperm. Nat Genet 6: 409-414, 1994.
405. Telenius H, Almqvist E, Kremer B, Spence N, Squitieri F, Nichol K, Grandell U, Starr E, Benjamin C, Castaldo I, Calabrese O, Anvret M, Goldberg YP, Hayden MR. Somatic mosaicism in sperm is associated with intergenerational (CAG)n changes in Huntington's disease. Hum Mol Genet 4: 189-195, 1995.
406. Tewari M, Quan LT, O'Rourke K, et al. Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly (ADP-ribose) polymerase. Cell 81: 801-809, 1995.
407. Thomas LB, Gates DJ, Richfield EK, O'Brien TF, Schweitzer JB, Steindler DA. DNA end labeling (TUNEL) in Huntington's disease and other neuropathological conditions. Exp Neurol 133: 265-272, 1995.
408. Thyagarajan D, Shanske S, Vazquez-Memije M, DeVivo D, DiMauro S. A novel mitochondrial ATPase 6 point mutation in familial bilateral striatal necrosis. Ann Neurol 38: 468-472, 1995.
409. Tomoda A, Ikezawa M, Ohtani Y, Miike T, Kumamoto T. Progressive myoclonus epilepsy: Dentato-rubro-pallido-Iuysian atrophy (DRPLA) in childhood. Brain Dev 13: 266-269, 1991.
410. Trottier Y, Biancalana V, Mandel J-L. Instability of CAG repeats in Himtington's disease: Relation to parental transmission and age of onset. J Med Genet 31: 377-382, 1994.
411. Trottier Y, Devys D, Imbert G, Saudou F, An I, Lutz Y, Weber C, Agid Y, Hirsch EC. Mandel J-L. Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. Nat Genet 10: 104-110, 1995.
412. Trottier Y, Lutz Y, Stevanin G, Imbert G, Devys D, Cancel G, Saudou F, Weber C, David G, Tora L, Agid Y, Brice A, Mandel J-L. Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias. Nature 378: 403-406, 1995.
413. Truong DD, Harding AE, Scaravilli F, Smith SJM, Morgan-Hughes JA, Marsden CD. Movement disorders in mitochondrial myopathies: A study of nine cases with two autopsy studies. Mov Disord 5: 109-117, 1990.
414. Ueno S, Kondoh K, Kotani Y, Komure O, Kuno S, Kawai J, Hazama F, Sano A. Somatic mosaicism of CAG repeat in dentatorubral-pallidoluysian atrophy (DRPLA). Hum Mol Genet 4: 663-666, 1995.
415. Uyama E, Kondo I, Uchino M, Fukushima T, Murayama N, Kuwano A, Inokuchi N, Ohtani Y, Ando M. Dentatorubral-pallidoluysian atrophy (DRPLA): Clinical, genetic, and neuroradiologic studies in a family. J Neurolog Sci 130: 146-153, 1995.
416. Van der Weiden RMF. George Huntington and George Sumner Huntington: A tale of two doctors. Hist Phil Life Sci 11: 297-304, 1989.
417. Van Dyk JF, van der Velde EA, Roos RAC, Bruyn GW. Juvenile Huntington disease. Hum Genet 73: 235-239, 1986.
418. Velier J, Schwarz, Young C, Fallon J, Hyman B, Martin EJ, Hughes S, Vallee R, Aronin N, DiFiglia M. Wild-type and mutant huntingtin localize to the Golgi complex and to vesicles in the peripheral cytoplasm in fibroblasts of control and HD patients [abstract]. Soc Neurosci 22: 26, 1996.
419. Vessie PR. On the transmission of Huntington's chorea for 300 years -the Bures family group. J Nerv Ment Dis 76: 553-573, 1932.
420. Vincent SR, Johansson O. Striatal neurons containing both somatostatin- and avian pancreatic polypeptide (APP)-like immunoreactivities and NADPH-diaphorase activity: A light and electron microscopic study. J Comp Neurol 217: 264-270, 1983.
421. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 44: 559-577, 1985.
422. Wallace DC, Hall AC. Evidence of genetic heterogeneity in Huntington's chorea. J Neurol Neurosurg Psychiatry 35: 789-800, 1972.
423. Wallace DC. Mitochondrial genetics: A paradigm for aging and degenerative diseases? Science 256: 628-632, 1992.
424. Wang HD, Greenberg CR, Hewitt J, Kalousek D, Hayden MR. Subregional assignment of the linked marker G8 (D4S10) for Huntington disease to chromosome 4p16.1-16.3. Am J Hum Genet 39: 392-396, 1986.
425. Wanker EE, Rovira C, Scherzinger E, Hasenbank R, Walter S, Tait D, Colicelli J, Lehrach H. HIP-1: A huntingtin interacting protein isolated by the yeast two-hybrid system. Hum Mol Genet 8: 487-495, 1997.
426. Warner JP, Barron LH, Brock DJ. A new polymerase chain reaction (PCR) assay for the trinucleotide repeat that is unstable and expanded on Huntington's disease chromosomes. Mol Cell Probes 7: 235-239, 1993.
427. Warner TT, Williams L, Harding AE. DRPLA in Europe. Nat Genet 6: 225, 1994.
428. Warner TT, Williams LD, Walker RWH, Flinter F, Robb SA, Bundey SE, Honavar M, Harding AE. A clinical and molecular genetic study of dentatorubropallidoluysian atrophy in four European families. Ann Neurol 37: 452-459, 1995.
429. Warren ST, Nelson DL. Trinucleotide repeat expansions in neurological disease. Curr Opin Neurobiol 3: 752-759, 1993.
430. Wasmuth JJ, Hewitt J, Smith B, Allard D, Haines JL, Skarecky D, Partlow E, Hayden MR. A highly polymorphic locus very tightly linked to the Huntington's disease gene. Nature 332: 734-736, 1988.
431. Watkins WS, Bamshad M, Jorde LB. Population genetics of trinucleotide repeat polymorphisms. Hum Mol Genet 4: 1485-1491, 1995.
432. Weigell-Weber M, Schmid W, Spiegel R. Psychiatric symptoms and CAG expansion in Huntington's disease. Am J Med Genet (Neuropsychiatric Genetics) 67: 53-57, 1996.
433. Wells RD. Molecular basis of genetic instability of triplet repeats. J Biol Chem 271: 2875-2878, 1996.
434. Wexler NS, Young AB, Tanzi RE, Travers H, Starosta-Rubinstein S, Penney JB, Snodgrass SR, Shoulson I, Gomez F, Ramos Arroyo MA, Penchaszadeh GK, Moreno H, Gibbons K, Faryniarz A, Hobbs W, Anderson MA, Bonilla E, Conneally PM, Gusella JF. Homozygotes for Huntington's disease. Nature 326: 194-197, 1987.
435. Wexler NS. The Tiresias complex: Huntington's disease as a paradigm of testing for late-onset disorders. FASEB J 6: 2820-2825, 1992.
436. Wharton KA, Yedvobnick B, Finnerty VG, Artavanis-Tsakonas S. opa: A novel family of transcribed repeats shared by the notch locus and other developmentally regulated loci in D. melanogaster. Cell 40: 55-62, 1985.
437. Wiggins S, Whyte P, Huggins M, Adam S, Theilmann J, Bloch M, Sheps SB, Schechter MT, Hayden MR. The psychological consequences of predictive testing for Huntington's disease. N Engl J Med 327: 1401-1405, 1992.
438. Witt TN, Danek A, Reiter M, Heim MU, Dirschinger J, Olsen EGJ. McLeod syndrome: A distinct form of neuroacanthocytosis. J Neurol 239: 302-306, 1992.
439. Wood JD, MacMillan JC, Harper PS, Lowenstein PR, Jones AL. Partial characterisation of murine huntingtin and apparent variations in the subcellular localisation of huntingtin in human, mouse and rat brain. Hum Mol Genet 5: 481-487, 1996.
440. Xuereb JH, MacMillan JC, Snell R, Davies P, Harper PS. Neuropathological diagnosis and CAG repeat expansion in Huntington's disease. J Neurol Neurosurg Psychiatry 60: 78-81, 1996.
441. Yanagisawa H, Fujii K, Nagafuchi S, Nakahori Y, Nakagome Y, Akane A, Nakamura M, Sano A, Komure O, Kondo I, Jin DK, Sørensen SA, Potter NT, Young SR, Nakamura K, Nukina N, Nagoa Y, Tadokoro K, Okuyama T, Miyashita T, Inoue T, Kanazawa I, Yamada M. A unique origin and multistep process for the generation of expanded DRPLA triplet repeats. Hum Mol Genet 5: 373-379, 1996.
442. Yazawa I, Nukina N, Hashida H, Goto J, Yamada M, Kanazawa I. Abnormal gene product identified in hereditary dentatorubral-pallidoluysian atrophy (DRPLA) brain. Nat Genet 10: 99-103, 1995.
443. Young AB, Penney JB, Starosta-Rubinstein S, Markel DS, Berent S, Giordani B, Ehrenkaufer R, Jewett D, Hichwa R. PET scan investigations of Huntington's disease: Cerebral metabolic correlates of neurologic features and functional decline. Ann Neurol 20: 296-303, 1986.
444. Young AB, Shoulson I, Penney JB, Starosta-Rubinstein S, Gomez F, Travers H, Ramos-Arroyo MA, Snodgrass SR, Bonilla E, Moreno H, Wexler NS. Huntington's disease in Venezuela: Neurologic features and functional decline. Neurology 36: 244-249, 1986.
445. Young AB, Greenamyre JT, Hollingsworth Z, Albin R, D'Amato C, Shoulson I, Penney JB. NMDA receptor losses in putamen from patients with Huntington's disease. Science 241: 981-983, 1988.
446. Zappacosta B, Monza D, Meoni C, Austoni L, Soliveri P, Gellera C, Alberti R, Mantero M, Penati G, Caraceni T, Girotti F. Psychiatric symptoms do not correlate with cognitive decline, motor symptoms, or CAG repeat length in Huntington's disease. Arch Neurol 53: 493-497, 1996.
447. Zech M, Roberts GW, Bogerts B, Crow TJ, Polak JM. Neuropeptides in the amygdala of controls, schizophrenics and patients suffering from Huntington's chorea: An immunohisto-chemical study. Acta Neuropathol 71: 259-266, 1986.
448. Zeitlin S, Liu J-P, Chapman DL, Papaioannou VE, Efstratiadis A. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat Genet 11: 155-163, 1995.
449. Zhuchenko O, Bailey J, Bonnen P, Ashizawa T, Stockton DW, Amos C, Dobyns WB, Subramony SH, Zoghbi HY, Lee CC. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha-voltage-dependent calcium channel. Nat Genet 15: 62-69, 1997.
450. Zoghbi HY. The expanding world of ataxins. Nat Genet 14: 237-238, 1996.
451. n repeat in the Huntington disease gene. Hum Mol Genet 2: 2063-2067, 1993.
452. Zweig RM, Koven SJ, Hedreen JC, Maestri NE, Kazazian HH Jr, Folstein SE. Linkage to the Huntington's disease locus in a family with unusual clinical and pathological features. Ann Neurol 26: 78-84, 1989.